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in elementary school that my homeroom teacher saw me sitting idly with nothing to 
do, and gave me a magazine she subscribed to, a magazine called Illustrert Vitenskap. 
I remember vividly reading about the concept of dendritic cells, these supposedly 
magnificent cells that could eradicate disease and potentially be the cure for cancer.  
So, when I got the opportunity in 2012 to join the medical student research 
programme, two projects caught my eye. The first one was investigating the effect of 
Chinese medicine on cancer cell lines and the other was developing dendritic cells for 
immunotherapy. I applied for both and soon after, I was welcomed to meet Roland 
Jonsson and Silke Appel at Broegelmann research laboratory. 
Looking back at it I remember one of the first things Silke remarked to me after our 
first meeting back in 2012, that surprisingly I wasn’t confusing dendritic cells with 
neural cells. Meanwhile Roland gleefully remarked that he could add another flag to 
his office, disregarding the fact I’m born in Norway as mere details as I could speak 
fluent Chinese. The international environment is exactly what I was missing having 
been in Bergen. Colleagues were welcoming and discussions could take place without 
much worry, which was very important to me. 
Silke for most parts is a paradox, stern but fair, understanding but blunt. It is hard for 
me to express how much gratitude I have towards you for your supervision and 
support during my time at the lab. It always amazes me at how many details you 
remember about things and the blistering pace you get things done. I highly doubt I 
would’ve gotten anywhere near where I am with the research without your guidance 
and supervision. Thanks for more or less being a motherly figure in all those years 
even though I’ve probably been a lazy kid for most parts. 
Roland is like our lab grandpa. Always looking out for everyone and trying to make 
everyone succeed with their projects. Our discussions about Sweden have always 
amused me as your love for your home country is only rivalled by your love for an 
inclusive international work environment. Thank you for all those years of support. 
Some of the first people I met were Brith Bergum and Richard Davies, who have 
helped me tremendously over the past 8 years with numerous difficulties. In fact, 
without your help, my hopeless chaotic nature would probably have been unable to 
move to my current apartment. Not just that, but this PhD dissertation would probably 
not have been possible without your help. So, thanks for helping me stay alive during 
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enjoyed Florian remarking about how he delivers my post and Romans love for 
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my other friends who have put up with the strange organism that is me.  
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bring, at least I don’t. If there’s anything I’ve learnt those past years, it is that life is 









Cancer is the leading cause of death in the developed world. While treatment options 
and detection have improved over the last century, mortality rate remains high 
especially in metastatic disease. Traditional treatment for metastatic cancer is often life 
prolonging with limited curative intentions. Furthermore, many traditional treatment 
regimens such as chemotherapy and radiotherapy have considerable side effects that 
drastically reduce quality of life. Prostate cancer is the second most common cancer in 
men worldwide and has limited treatment options with curative intention.  
The introduction of checkpoint-inhibitors in treatment of melanoma showed that 
immune-response against cancer is possible, and that patients who respond have long 
survival.  
Dendritic cell-based immunotherapy has shown to work in animal models and is a 
promising method to stimulate an immune response against cancer. One of the easiest 
methods to obtain dendritic cells (DC) is by generation from monocytes. These 
monocyte-derived DC (moDC) can be loaded with antigens and used to stimulate 
immune responses. However, recent clinical trials using moDC for immunotherapy 
showed disappointing results.  
The overall goal of this thesis was to investigate factors that affect the properties of 
moDC such as culture conditions and maturation stimuli and how that affects their 
interaction with T-cells. 
In paper I the effect of OK432 as a maturation stimulus for moDC was investigated in 
various formats. Properties such as phenotype, cytokine profile, migratory capacity 
and T-cell stimulatory capacity was measured. The addition of PGE2 resolved the lack 
of migratory capacity in OK432 matured moDC. It was concluded that OK432 
together with CL097 and PGE2 is a promising cocktail for moDC maturation in 
immunotherapy. 
In paper II the effects of the culture dish surface on the generation of moDC was 
investigated. Properties such as phenotype and cytokine profile were measured. 
Overall, the surface adhesion properties of cell culture dishes used significantly 
affected many properties of moDC in both immunogenic and tolerogenic culture 
conditions. 
In paper III, moDC from patients with metastatic prostate cancer were investigated to 




OK432 cocktail developed in paper I. MoDC from patients showed a mature 
phenotype and were able to stimulate autologous T-cells in an antigen-specific 

























List of Publications & manuscripts 
The doctoral thesis is based on the following publications. 
I. Yi, D.H., Stetter, N., Jakobsen, K., Jonsson, R., Appel, S. (2018). 3-Day 
monocyte-derived cells stimulated with a combination of OK432, TLR7/8 
ligand, and prostaglandin E2 are a promising alternative for cancer 
immunotherapy, Cancer Immunol Immunotherapy 67, 1611–1620    
 
II. Sauter, A., Yi, D.H., Li Y., Roersma, S., Appel, S. (2019). The Culture Dish 
Surface Influences the phenotype and Cytokine Production of Human 
Monocyte-Derived Dendritic Cells, Frontiers in Immunology  10: 2352. 
 
III. Dag H. Yi, Waqas Azeem, Anne Margrete Øyan, Karl-Henning Kalland, Silke 
Appel. Effect of different maturation stimuli on phenotype and function of 














The published papers are reprinted with permission from Springer Nature and CC-






AIDS acquired immunodeficiency 
syndrome 
moDC monocyte derived dendritic 
cell 
AP-1 activator protein 1 NACs non-adherent cells 
APC antigen presenting cell NK cell natural killer cell 
BCR B-cell receptor PAMP pathogen associated 
molecular pattern 
BCR-ABL Breakpoint cluster region-
Abelson tyrosine kinase 
oncogenic fusion gene 
PBMC peripheral blood 
mononuclear cell 
CAF cancer-associated fibroblast PD-L1 programmed death ligand 1 
CAR-T Chimeric antigen receptor 
T  
PD-L2 programmed death ligand 2 
CCR7 CC-chemokine receptor 7 PMTs photomultiplier tubes 
CRISP/CAS9 clustered regulatory 
interspaced short 
palindromic repeat 






diacetate succinimidyl ester 
PRR pattern recognition receptor 
CML in chronic myelogenous 
leukemia 
TAM tumour associated 
macrophage 
CTL cytotoxic T-lymphocyte TBK1 TANK-binding kinase 1 
CTLA-4 cytotoxic T-lymphocyte-
associated protein 4 
TCR T-cell receptor 
DAMP damage associated 
molecular pattern 
TGF-β transforming growth factor 
beta 
DC dendritic cell Th 
cells 
T-helper cells 





TLR Toll-like receptor 
FMO Fluorescence Minus One TMB tumour mutational burden 
GM-CSF granulocyte-macrophage 
colony-stimulating factor 
TNF- α tumour necrosis factor α 
HIV human immunodeficiency 
virus 
TNM The TNM Classification of 
Malignant Tumors (T-tumor, 
N-lymph node, M-
metastasis) 




IgG immunoglobulin G TRIF TIR-domain-containing 
adapter-inducing interferon-
β 
IL Interleukin UICC Union for International 
Cancer Contro 
IRF3/7 interferon regulatory factor 
3/7 
V(D)J Variable gene segments, 
Diversity gene segments and 
Joining gene segments 
LPS lipopolysaccharides VEGF vascular endothelial growth 
factor 
MAPK mitogen-activated protein 
kinase 
WHO World Health Organization 
MHC I major histocompatibility 
complex class I 
  
MHC II major histocompatibility 
complex class II 
  




















Scientific environment .................................................................................................. 3 
Acknowledgements ......................................................................................................... 4 
Abstract ........................................................................................................................... 6 
List of Publications & manuscripts ................................................................................. 8 
Abbreviations .................................................................................................................. 9 
1. Introduction ............................................................................................................ 13 
1.1 The importance of the immune system ........................................................... 13 
1.1.1 The innate immune system ....................................................................... 14 
1.1.2 Receptors and signalling pathways of the innate immune system ........... 15 
1.1.3 Immune cells of the innate immune system ............................................. 18 
1.1.4 Limitations of the innate immune system ................................................ 20 
1.2 The adaptive immune system .......................................................................... 22 
1.2.1 The development and cells of the adaptive immune system .................... 22 
1.2.2 The functions of the adaptive immune system ......................................... 26 
1.2.3 The vulnerabilities of the adaptive immune system ................................. 28 
1.3 Cancer .............................................................................................................. 29 
1.3.1 Cancer as a genetic disease ....................................................................... 30 
1.3.2 Immune evasion in cancer ........................................................................ 32 
1.3.3 Classical therapies for cancer and limitations .......................................... 35 
1.3.4 Prostate cancer .......................................................................................... 38 
1.4 Immunotherapy ............................................................................................... 39 
1.4.1 Dendritic cell immunotherapy .................................................................. 40 
1.4.2 The rise of checkpoint inhibitors .............................................................. 44 
1.4.3 OK432 in immunotherapy ........................................................................ 47 
1.4.4 Challenges of immunotherapy .................................................................. 47 
1.4.5 Challenges of immunotherapy in prostate cancer .................................... 49 
2. Aims ....................................................................................................................... 50 




3.1 Cohort information ....................................................................................... 51 
3.2 Blood collection, PBMC and monocyte isolation and cryopreservation ..... 51 
3.3 Cell culture, DC generation and maturation ................................................ 52 
3.4 Blocking antibodies ..................................................................................... 54 
3.5 moDC – NACs co-culture ............................................................................ 54 
3.6 Flow cytometry ............................................................................................ 55 
3.7 Chemotaxis assay ......................................................................................... 59 
3.8 IFN-γ secretion assay ................................................................................... 60 
3.10 ELISA (Paper I) ........................................................................................ 60 
3.11 Luminex assay .......................................................................................... 61 
3.12 Data analysis ............................................................................................. 61 
4. Summary of the main results.................................................................................. 62 
5. Discussion .............................................................................................................. 66 
5.1 Methodological considerations ....................................................................... 66 
5.1.1 Culture, treatment and storage condition of cells ..................................... 66 
5.1.2  Considerations in moDC stimulation ....................................................... 67 
5.1.3 Special considerations on MLR ................................................................ 67 
5.1.4 Special considerations on flow cytometry ................................................ 68 
5.1.5 Special considerations on migration assay ............................................... 69 
5.1.6 Special considerations on IFNγ assay ...................................................... 69 
5.1.7 Special considerations on ELISA ............................................................. 70 
5.2 Implications of research results ....................................................................... 70 
5.2.1 The role of OK432 in moDC maturation and the effects of PGE2 .......... 71 
5.2.2 Cell culture surface should not be ignored ............................................... 73 
5.2.3 Challenges with studying cells from cancer patients ............................... 75 
6. Conclusions ............................................................................................................ 77 
7. Future perspectives ................................................................................................. 78 
8. References .............................................................................................................. 80 








1.1 The importance of the immune system 
Since the dawn of life, the ecosystem is in a constant evolutionary race striving for 
survival through various methods. The main categories of life sustenance can broadly 
be categorized into primary producers, such as photosynthetic plants and subsequent 
consumers which involve herbivores and their predators. The most prevalent form of 
energy consumption among species is parasitism, siphoning energy from the 
organism’s host. Without protection from parasitism, host organisms suffer the 
consequences of lower energy efficiency and usually lower chance of survival[1]. In 
the context of an infection with parasitical bacteria, viruses, fungi, protozoa or 
helminths, they are called pathogens, but this can also include malignant conditions 
which by extension can also be considered parasitical due to their energy draining 
features [2-4]. There are however also organisms that strive on symbiotic relationships 
with their host organism, which while surviving on the energy their hosts provide  
benefit the host organism overall through mechanisms such as aid in digestion[5]. 
While co-existing in this environment, it is in the best interest of living organisms to 
deter parasites and either encourage or ignore symbiotic relationships. To this end, 
larger multicellular-organisms have evolved a complex multi-layered system capable 
of distinguishing and rejecting harmful organisms from safe organisms called the 
immune system which is crucial for survival and many animal studies have shown that 
a disabled immune system often leads to early demise in a non-sterile environment or 
upon challenge with a pathogen[6, 7]. The human immune system is no exception. 
This leads to an evolutionary race between the parasitical pathogens and the human 
immune system where pathogens continuously evolve new ways to evade rejection 
from their hosts for their own survival. As the replication rate of most pathogens are 
considerably higher than that of humans, the mutational drive is in their favour. As 
congenital specific detection of each new mutation in the myriads of pathogens is 
impossible for the slow replicating larger host organisms, their immune system has 




germline preserved innate immune system for broad general protection, and an 
adaptive immune system hypermutating to specialize against specific pathogens[8]. 
1.1.1 The innate immune system 
Often regarded as the first line of defence, the innate immune system is the 
evolutionary preserved part and is especially important early in life. One of the most 
obvious defences against pathogens are physical barriers such as our skin. Not only 
does it act as a physical barrier, but skin cells also secrete anti-microbial peptides such 
as defensins and cathelicidins which are capable of neutralizing many different 
pathogens[9]. The mucosa lining the gastrointestinal tract, the respiratory tract and the 
urogenital tract also contain both physical and chemical properties to deter pathogenic 
infection[10, 11]. Past the outer barriers, the liver also secretes immunogenic proteins 
as part of the complement system which is capable of neutralizing and coat pathogens 
through a process called opsonization. This not only has the potential of neutralizing 
pathogens, but also makes opsonized pathogens easier to detect for the rest of the 
immune system. Apart from barriers of the innate immune system, there are many 
different specialized cells with unique roles that comprise the active part of the innate 
immune system consisting of macrophages, neutrophils, eosinophils, natural killer 
cells (NK cells), monocyte, dendritic cells (DCs) and others as shown in figure 1 [12]. 
Lately a new class of innate immune cells were classified into three different groups in 
2013 by Spits at al named innate lymphoid cells that appears to be important in 
mucosal immunity but are not shown in the figure [13]. How innate immune cells 
function, communicate with other cells and react to their environment is dictated by 
chemical signalling molecules of the immune system called cytokines such as 
interferons (IFN), interleukins (IL), and chemokines as well as surface proteins such as 
adhesion molecules affects the tissue localization of immune cells and how they bind 





Figure 1. Overview of the central role dendritic cells play in the immune system. Upon 
activation of dendritic cells through antigen binding to pattern-recognition receptors, 
including C-type lectin receptors, leucine-rich repeat-containing receptors and Toll-
like receptors, dendritic cells will secrete cytokines that activate natural killer cells 
and modulate T cell differentiation. Recognition of antigen-Major Histocompatibility 
Complex on dendritic cells by the T Cell Receptor will also impact on T cells 
expansion. Figure adapted from Silva et al [15]. Reprinted and modified with 
permission from Elsevier  
 
1.1.2 Receptors and signalling pathways of the innate immune system 
While pathogens are continuously replicating and mutating, most of them have 
evolutionary conserved regions that the cells of the innate immune system have 
evolved receptors for. In fact, immune cells have myriads of different receptors 
targeting various pathogenic stimuli. These pattern recognition receptors (PRRs) can 
recognize components directly from pathogens called pathogen associated molecular 
patterns (PAMPs) such as lipopolysaccharides (LPS) which are absent in all human 




most researched PRRs belong to the group called Toll-like receptors (TLR) which 
humans have 10 of and comprises of 6 surface receptors and 4 intracellular receptors 
as shown in figure 2 [18].  
 
 
Figure 2. Overview of Toll-like receptors found in human and mouse, main ligands 
and cellular localization (hTLR and mTLR denote Toll-like receptor retricted to 
human and mouse respectively). Figure republished with permission from El-Zayat et 
al [18]. 
 
Each Toll like receptor triggers an intracellular downstream signalling cascade upon 
binding to its respective PAMP ligand, usually resulting in the activation of NFκB 
through the MyD88 pathway or TIR-domain-containing adapter-inducing interferon-β 
(TRIF) pathway. A simplified overview of the main TLR activated signalling cascades 






Figure 3. Intracellular signalling pathways involved in cellular responses to Toll-like 
receptor activation. Following TLR binding to its corresponding ligand information is 
transferred through a series of steps ultimately resulting in the transcription of genes 
modifying cellular responses. TLR activation commonly leads to the production of 
Type I IFN though the activation of interferon regulatory factor (IRF) and 




NFκB is a key regulator of many genes involved in inflammation and controls among 
others the production of pro-inflammatory cytokines in immune cells. TRIF activation 
can also lead to activation of TANK-binding kinase 1 (TBK1), subsequently ending in 
production of type 1 interferons through translocation of phosphorylated interferon 
regulatory factor 3/7 (IRF3/7) into the cell nucleus [20]. An additional branch for both 
pathways mentioned above is through activation of mitogen-activated protein kinase 
(MAPK) resulting in activation of activator protein 1 (AP-1) which regulates genes 
affecting proliferation[21]. The immune cells have also evolved receptors to detect 
signals of cellular stress and destruction, such as free deoxyribonucleic acid (DNA), 
organelle components or other cell particles normally not in the extracellular matrix, 
called damage associated molecular patterns (DAMPs). These receptors are crucial for 
immune cells to detect pathogens and cellular damage in the surrounding tissue and 
highly dictate their subsequent response to such stimuli [17, 22]. 
1.1.3 Immune cells of the innate immune system 
Usually the first cells to encounter infiltrating pathogens, macrophages are immune 
cells residing in tissues and received its name due to its size and strong ability to “eat” 
particles in a process called phagocytosis which is one of the methods used by immune 
cells to neutralize pathogens. Apart from their role in combating pathogens, they play 
a key role in regulating the response of the immune system as well as regulating tissue 
repair after local damage. Cross-talk between macrophages and other immune cells is 
vital in determining how the immune system reacts towards pathogens as they have the 
ability to promote inflammation by secreting proinflammatory cytokines such as 
tumour necrosis factor α (TNF-α) and recruiting other immune cells, notably 
neutrophils through chemokines such as IL-8, to neutralize potential pathogens 
causing the inflammation. In this inflammatory state, they are often called M1 
macrophages. However, they also play a key role in tissue repair and 
immunosuppression in the absence of pathogenic stimuli which is often referred to as 
M2 macrophages. Macrophages are alongside DCs considered antigen presenting cells 
(APCs) because of their ability to process and present peptide antigens on major 




Neutrophils are the most numerous immune cells usually numbering over half the total 
amount of white blood cells in humans. They are blood circulating immune cells that 
respond to inflammation and recruited through localized vasodilation caused by tissue 
residing cells and subsequent migration into target tissue. As the most abundant innate 
immune cell, they have strong anti-pathogenic capabilities through phagocytosis, 
degranulation resulting in release of degrading enzymes and creation of extracellular 
traps formed by DNA fibers and proteins [27]. 
Monocytes are large blood circulating immune cells with the capability of developing 
into macrophages. They are able to migrate into tissue to replenish local macrophage 
numbers and under certain circumstances develop into DCs. While monocytes do have 
antigen presenting capabilities similar to their post-differentiated specialized versions, 
whether this has a function in their undifferentiated form in vivo remains unclear [25, 
28].  
Eosinophils, basophils and mast cells are important cells for their anti-helminthic 
responses being able to stimulate and coordinate physiological and immunological 
reactions against large pathogens otherwise highly resistant to other immune cells [29-
31]. 
NK cells are often regarded as the innate immune system’s anti-viral specialists as 
they can neutralize infected host cells. They are considered the primary immune cells 
capable of eliminating cells not expressing major histocompatibility complex class I 
(MHC I) through probing cell surfaces with various MHC I binding receptors. This 
mechanism usually acts as a safeguard against pathogens or malignancies that attempt 
to hide from the immune system through manipulating antigen presenting functions 
[32].  
Dendritic cells are one of the most recently discovered immune cells by Steinman and 
Cohn in 1973 and are often described both as sentinel cells and as professional APCs 
[33]. This is because unlike macrophages who primarily affect and regulate local 
tissue site, the primary role of DCs is to present antigens to other immune cells and 
communicate the context of the antigen presented. Acting as the scouts of the immune 




antigens from most of the human body. Upon uptake of antigen together with 
stimulation, DCs undergo a maturation process which enhances their ability to present 
antigens by upregulating expression of MHC class II and costimulatory molecules 
CD80 and CD86 as well as upregulate their expression of CC-chemokine receptor 7 
(CCR7) which stimulates chemotaxis towards lymph nodes to meet näive T-cells. A 
commonly used marker for mature DC is CD83 as it is clearly upregulated in mature 
DCs, but its function is as of yet not very clear [34]. Those antigen presenting 
properties and their ability to activate cells of the adaptive immune system are why 
DCs are considered the link between the innate and the adaptive immune system [35, 
36].  
1.1.4 Limitations of the innate immune system 
As the evolutionary conserved part of the immune system, innate immune cells are by 
nature limited in their specificity as their PRRs are germline encoded. While this can 
protect against most pathogenic species, there are many exceptions. As pathogens 
replicate and mutate, strains develop that have properties that helps avoiding the 
immune system. This could be by hiding or weakly express conserved regions to avoid 
strong PRR binding, changing properties of capsule or membrane to resist detection or 
neutralization, manipulating immune cell signalling pathways, structure mimicry to 
host antigens, release of decoy superantigens and by various other means as shown in 
figure 4. While some cells of the innate immune system have shown memory function 
and degrees of adaptability, it is not enough to overcome all the immune evasive 
strategies pathogens evolve. To cover the insufficiencies of the innate immune system, 
slower replicating organisms evolved the adaptive immune system to overcome those 
constraints and widely believed to have originated from Gnathostomes hundreds of 





Figure 4. Immune evasion strategies of viral and bacterial pathogens. Viral and 
bacterial pathogens employ a number of strategies to avoid mediators of an immune 
response and their subsequent destruction. These strategies range from inhibition of 
antigen presentation and inflammatory responses, inhibition of phagocytosis and 
modulation and degradation of cellular receptors. Figure from Finlay and McFadden 







1.2 The adaptive immune system  
As pathogens continuously evolve and acquire new structural changes that can 
interfere with detection by our germline inherited PRRs, it is unfeasible for every 
immune cell to be capable of reacting against every possible genetic rearrangement of 
these new pathogenic strains or pre-emptively have enough quantity of diverse 
immune cells to cover every possible new strain. To solve this conundrum, the 
adaptive immune system has evolved with a reactive strategy that maintains very high 
variability in what it can react against that only gets expanded when required in a 
process called clonal expansion. In comparison to the innate immune system, the 
adaptive immune system requires time to adapt to new challenges but offers a much 
more robust and specific immune response [8]. 
1.2.1 The development and cells of the adaptive immune system 
The adaptive immune system mainly consists of T-cells and B-cells and their subtypes 
and the humoral immunity. Compared to the innate immune system, the adaptive 
immune system has a much wider repertoire of possible antigens it can recognize. 
The way which the adaptive immune system can cover such a diverse repertoire of 
potential receptors for new antigens is due to somatic recombination of Variable gene 
segments, Diversity gene segments and Joining gene segments (V(D)J). These gene 
segments are responsible for coding the binding site of adaptive immune cell receptors 
called B-cell receptors (BCR) and T-cell receptors (TCR) for B and T cells, 
respectively. Due to the highly diverse ways which the V(D)J segments can be 
rearranged and recombined, the resulting TCRs and BCRs are able to bind to novel 
antigens that have never been encountered before [43, 44].  
As mentioned previously, due to V(D)J recombination during the development of 
progenitor adaptive immune cells, peptides expressed in our own body are not 
excluded from this coverage. As mounting an immune reaction towards the host’s own 
cells is highly detrimental, it is crucial to neutralize immune cells which can bind self-
peptides in an immunogenic way, known as autoreactive immune cells. The process of 




of self-exclusion by the immune system called central tolerance. Similarly, immune 
cells which do not have the capability of mounting a strong immune response are of 
limited use to the immune system and are therefore also removed. To undergo these 
processes, a specialized organ prominent in childhood called the thymus is where 
progenitor cells undergo maturation by receiving a survival stimuli if they bind 
strongly to MHC molecules and a signal to undergo programmed cell death (apoptosis) 
or go into anergy if they bind strongly to self-peptides presented by medullary thymic 
epithelial cells. Some of the self-reactive immune cells can also turn into protective 
regulatory cells that inhibits immune reactions towards their antigen. A similar process 
also happens with B-cell progenitors in the bone marrow where positive and negative 
selection also occur [45-48].  
The key to an adaptive immune response lies with how it interacts with MHC 
molecules which are one of the main triggers activating the adaptive immune cells. As 
previously mentioned, the immune system keeps a vast repertoire of immune cells 
capable of reacting towards various peptides, but without having their ligand presented 
to them, they remain circulating and inactive. These cells are called näive immune 
cells and they circulate between peripheral lymph nodes. [49, 50]. As the primary 
presenter of antigens from peripheral tissue to immune cells residing in the lymph 
node, DCs are the primary activators of an adaptive immune response in T-cells. How 
DCs present the antigen is crucial in determining what type of response the naïve T-
cells will have and this can generally be split into 3 key signals as shown in figure 5, 
the first being the peptide presented on MHC binding to the TCR, the second being co-
stimulatory or inhibitory molecules on the surface of the cells binding to their ligands 
and the third being the secreted cytokines from the DCs [51]. If all 3 signals are pro-
inflammatory, bound naïve T-cells are selected to undergo a process called clonal 
expansion where T-cells with the strongest binding to the antigen presented undergoes 
extensive division resulting in large amounts of clonal daughter cells [52, 53]. Naïve 
B-cells also undergo a similar process where strong attachment to presented antigens 





The 3 signals determine which subset of adaptive immune cells gets clonally expanded 
and influences their function. In the context of a peptide presented in the context of 
high co-stimulatory signals from CD80 and CD86 on the surface of DCs together with 
secreted proinflammatory cytokines such as IL-12p70, naïve T-cells can develop into 
effector CD4+ T-helper cells (Th cells) or CD8+ cytotoxic T-lymphocytes (CTLs). 
Conversely if the signals skew towards inhibitory signals such as expression of 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T-cells or programmed 
death ligand 1 (PD-L1) and 2 (PD-L2) on DC, which are part of signal 2 together with 
secretion of regulatory cytokines such as transforming growth factor beta (TGF-β) as 
part of signal 3, leads to no reaction or expansion of regulatory T cells (Tregs) that 





Figure 5. The three signals of antigen presentation. T cell activation requires three 
signals from APCs such as DCs to become activated or primed. First, T cells must 
recognise their cognate antigen in context with HLA. Second, T cells require a 
costimulatory signal (CD80/86) from the APC. Finally, cytokines from immune cells 
and the microenvironment determine the T cell phenotypic fate. Conversely APCs can 
inhibit T cell responses through presentation and binding of programmed death ligand 
1 (PD-L1) and 2 (PD-L2) with T-lymphocyte-associated protein 4 (CTLA-4) together 
with regulatory cytokines. Figure from Yi and Appel 2013 [51] republished with 




1.2.2 The functions of the adaptive immune system 
Due to the selective nature of how effector cells of the adaptive immune system 
develops as described in the previous section, the adaptive immune response is much 
more specific than the innate immune system and can thus mount a much more robust 
immune response with very small risk of autoreactivity. The immune response can 
roughly be split into two categories, namely cellular immunity and antibody mediated 
immunity also known as humoral immunity [8, 58, 59]. 
T-cells are the cells responsible for cellular immunity and different subsets carry 
different roles. The 3 main subtypes of T-cells are CD4+ Th-cells, CD8+ CTLs and 
Tregs. Th-cells mediate immune responses by secreting cytokines and providing 
stimuli to other immune cells, notably macrophages and B-cells, to mount a much 
stronger immune reaction than they would otherwise. This results in more rapid 
phagocytosis and elimination of pathogens expressing the peptide binding to the Th-
cells. They are also vital in regulating the response of other immune cells such as 
CTLs and NK cells through cross talk [41, 60-62]. The response they induce is highly 
dependent on the phenotype as well as the cytokine profile of these cells such as 
expression of CD40L on the surface and secretion of IL-6 and IFNγ [63, 64]. 
CTLs on the other hand take a more direct approach in eliminating pathogens by 
storing and releasing granules containing perforins and granzymes upon being 
presented their TCR specific peptide by MHC on target cells [65]. They are especially 
adept at eliminating targets that hide within other cells and therefore resistant to 
phagocytosis such as viruses and are also vital in eliminating own cells that express 
PAMPs associated with malignancy [66, 67].  
A prolonged immune response can be highly detrimental as chronic inflammation is 
related to various ailments and can often result in diseases or be part of a group of 
diseases called autoinflammatory diseases if no autoantigen is known [68]. Therefore, 
it is important to not prolong immunogenic responses more than necessary and to 
tolerate harmless or symbiotic organisms such as many gut bacteria. If the immune 
system is unable to completely neutralize a pathogen after prolonged immune activity 




learns to tolerate it. Tregs are the key regulatory cells responsible for suppressing 
unwanted immune responses against such targets and are prevalent in tissue close to 
symbiotic or harmless organisms. They do so by secreting immunosuppressive 
cytokines such as IL-10 and TGF-β as well as expressing inhibitory surface molecules 
such as CTLA-4 [69-71].  
The humoral immunity provided by B-cells consists of antibodies which are secreted 
BCRs. Depending on the type of stimuli they receive during the maturation process, 
the receptor undergoes isotype switching to fit the context in which the target chemical 
molecule is presented. Similarly to the proteins of complement system of the innate 
immune system, but in a much more specific manner, antibodies coat and opsonize 
their targets both to label them as targets for other immune cells as well as neutralizing 
the functions of the target [8, 72, 73].     
A shared trait among adaptive immune cells is the need for continuous survival 
stimuli. This is in the form of cytokines such as IL-2, a key survival signal, which is 
auto secreted by T-cells upon binding antigen to their respective TCR. In B-cells, 
several cytokines such as IL-21 and IL-4 are considered survival signals and are 
mainly secreted by Th-cells residing in the follicles of lymph nodes [74-76]. However, 
once the target peptide is eliminated from the body and survival stimuli is no longer 
provided, most of the effector cells of the adaptive immune system undergo apoptosis 
as they no longer are needed. However, a subpopulation of long surviving dedicated 
memory cells of both T and B lineage remains post-clearance of antigen in anticipation 
of a reoccurrence of their target antigen and are ready to undergo clonal expansion 
upon re-detection of target antigen. This way the adaptive immune response bypasses 
the time needed during novel naïve activation of adaptive immunity as well as 
immediately clonally expand antigen specific T-cells which is why establishment of 





1.2.3 The vulnerabilities of the adaptive immune system  
While the adaptive immune system is extremely powerful and versatile, it is not 
without its flaws. There is a possibility for central tolerance to fail, and autoreactive 
immune cells escape neutralization which can lead to autoimmune diseases such as 
Myasthenia Gravis and Systemic lupus erythematosus [48, 80, 81]. Even if the 
adaptive immune system targets a pathogen associated antigen, the response needs to 
be appropriate for the purpose of eliminating the threat. If the immune response is not 
robust enough, the pathogen might escape elimination resulting in continuation of the 
disease, but conversely if the immune reaction is too strong, it can lead to a breakdown 
of immune regulation and cause a deadly physiological condition called a cytokine 
storm [82, 83].  
There are also ways how pathogens can evade even the adaptive immune system by 
similar mechanism to how pathogens evade the innate immune system such as 
mimicry, diversion with superantigens or even directly inactivating components of it. 
A well-known pathogen that is capable of deactivating the adaptive immune response 
is human immunodeficiency virus (HIV) which infects CD4+ Th-cells resulting in 
their eventual destruction and leading to acquired immunodeficiency syndrome 
(AIDS) [84, 85].  
The ability to undergo clonal expansion can also be a double-edged sword in some 
circumstances if the regulatory mechanisms such as requirement of survival stimuli 
fail, a rapid uncontrolled expansion of immune cells leads to a group of cancers called 
lymphomas and leukemias [86, 87].           
Overall, the innate and adaptive immune systems complement each other by covering 
many of each other’s weaknesses, namely the innate immune system covering for the 
slow initial phase of the adaptive immune response and the adaptive immune system 
covering for the innate immune systems limited repertoire of receptor specificity. 
Together this makes for a very powerful biological system that has protected us since 





Humans are living longer than they have ever lived before. Myriads of factors 
contributing to this are among others the advance of modern medicine and better 
coverage for necessities such as clean water, food security and housing has drastically 
improved life expectancy all over the world. The introduction of vaccines has 
drastically reduced death by previously common diseases such as smallpox and polio 
[88, 89]. In fact the rapid rise of average life expectancy all over the world since the 
past century is lauded as one of the greatest accomplishments in human history and is 
still projected to continue rising in the future [90, 91]. General better health awareness 
and better access to a diverse diet has also reduced the impact of lifestyle related 
mortality factors such as smoking and cardiovascular diseases in high income 
countries [92-94]. As cancer is a disease with incidence risk increasing by age, all of 
those factors has led to cancer becoming the most common cause of death in 
developed countries [95-97]. 
Cancer is one of the leading causes of death worldwide with the World Health 
Organization (WHO) reporting 9.6 million casualties in 2018 and accounts for almost 
double the amount of deaths compared to cardiovascular diseases in developed 
countries [95, 98]. Cancer is a very broad group of different diseases with different 
mortalities, progression and symptoms but with certain common traits. In one of the 
most influential papers published about cancer in 2011 titled “Hallmarks of Cancer: 
The Next Generation”, Hanahan and Weinberg outline eight biological conditions that 
are hallmark features of cancer [4]. These consist of evading growth suppressors, 
avoiding immune destruction, enabling replicative immortality, tumour-promoting 
inflammation, activation of invasiveness and metastasis, inducing angiogenesis, 
genome instability and mutation, resisting signals of cell death, deregulation of cellular 
energetics and sustaining proliferative signalling as shown in figure 6. This modern 
interpretation of cancer activity has paved the way for more targeted therapies against 
these hallmarks [99-103]. However, many such targeted therapies are only recent 




   
Figure 6. The hallmarks of cancers and potential targets for therapy as presented by 
Hanahan and Weinberg 2013. Cancers acquire functional capabilities that allow 
cancer cells to survive and proliferate (inner ring). Drugs which interfere with these 
capabilities have been developed for their potential use as cancer therapeutics. Figure 
from Hanahan and Weinberg 2013 [4]. Republished with permission from Elsevier.     
 
1.3.1 Cancer as a genetic disease  
Unlike pathogens such as bacteria and viruses, cancer is by its nature a disease caused 
by genetic modification of our own cells leading to uncontrolled growth. Every time a 
cell undergoes mitosis, its DNA must be pulled apart and replicated. Each time this 
happens, there is an inherent risk of spot mutations or minor changes to the genome 
during the replication stage. Mutations can also be instigated by viruses that alter the 
genome for their own survival and replication such as Epstein-Barr virus and Human 




beautifully in the concept by Darwin in his revolutionary work “On the Origin of  
Species” where mutations positively affecting a cells contribution to the survival of its 
multicellular system gets its genome inherited by its descendants [104]. By the same 
system, there is a risk of mutations hitting key growth regulating genes resulting in 
uncontrollable growth or mutations rendering the cell unviable. To prevent this from 
occurring, our cells have many checks and balances involving various enzymes that 
scan and repair genetic errors during mitosis. Our genome also encompasses sequences 
coding for proteins acting as regulators of growth and genetic stability[105]. 
One of the most studied and most commonly occurring mutation resulting in cancer 
are mutations in sections of the tumour protein p53 gene, a transcription factor 
comprising of five regions with high degree of conservation crucial in maintaining 
genetic stability and regarded as one of the most important tumour suppressor genes 
[106]. Ever since its discovery in 1979, its role in cancer has been extensively studied 
and many experiments have shown that it is vital for cell-cycle arrest, induction of 
senescence or induction of apoptosis in cells before they develop into cancers. 
Knockout experiments of p53 in mice have shown that these mice have a dramatically 
reduced lifespan solely due to development of early tumours cementing the importance 
of tumour suppressor genes in preventing cancer [107-109]. 
While tumour suppressor genes are important in the prevention of cancer, there are 
also genes that are over-expressed or mutated in certain types of cancers that 
contribute to their growth and survival referred to as oncogenes. Prominent examples 
include HER2 and BRCA1/2 in breast cancer [110, 111] and BCR-ABL in chronic 
myelogenous leukemia (CML) [112, 113].  
Further evidence of cancer being a genetic disease can be observed epidemiologically 
by assessing environmental risk factors. A key driver for mutations is oxidative stress 
and tissue conditions that promote this such as chronic inflammation or lifestyle habits 




1.3.2 Immune evasion in cancer 
As previously mentioned, most potential cancers are stopped at conception by checks 
and balance mechanisms during DNA replication. However, even if tumour suppressor 
genes fail to stop the development of cancer, there is emerging evidence for the role of 
immune surveillance, the hypothesis that many pre-cancerous cells are eliminated by 
the immune system before they can develop into full blown cancer by recognizing 
onco-antigens as non-self. Several animal experiments show rejection of 
transplantation of tumour tissue in syngeneic animals, but tolerance of healthy tissue. 
This alongside detection of tumour infiltrating lymphocytes (TILs) in the grafts upon 
rejection provides evidence that the immune system is capable of detecting onco-
antigens and react against cancer [118, 119]. While tumour graft experiments cannot 
be conducted on human twins for ethical reasons, TILs are highly associated with 
better prognosis in many types of cancers [120-122]. Many of the discoveries in 
animal models regarding immune surveillance, however, have been hard to translate 
into human settings as concepts such as IFNγ and perforin treatment that appear to 
contribute to anti-tumour immune responses in mice were not observed in human 
patients of various cancer types [123]. 
The prevalent model for immune outcomes regarding cancer is the concept of the three 
E’s, namely Elimination, Equilibrium and Escape [124]. As discussed previously, 
there is ample evidence that the immune system is indeed able to eliminate cancers. 
However, cancers are not homogenic diseases, and unless the immune system manages 
to eliminate all cancer cells, it might instead promote Darwinian selection of the cells 
that escape elimination. Equilibrium is the proposed state in which immune cells 
continue to eliminate and control the growth of detectable tumour cells, but at the 
same time driving a selective survival of immune resistant tumour cell strains. The 
final phase of this model results in immunological escape, where detectable tumour 
strains have mostly been eliminated and now the tumour consists primarily of immune 






Figure 7. The three E’s of cancer immunity (Elimination, Equilibrium and Escape). 
The figure illustrates the prevalent model for immune outcomes regarding cancer. In 
the elimination phase, innate and the adaptative systems act to destroy developing 
tumors. If unsuccessful and a rare cancer cell variant survives, it may enter the 
equilibrium phase, where outgrowth is prevented by actions of components of the 
immune system in particular T cells, NK cells, IL-12 and IFNγ. An outcome of 
selective pressure on tumor cells may result in tumor cells that are able to escape the 
regulation by the immune system. These tumor cells enter the escape phase and cause 
clinically apparent disease. Figure from Schreiber et al 2011. Reprinted with 





Due to the nature of cancer originating as a genetic defect of our own cells, they are 
inherently different from pathogens who have clear components or molecular patterns 
that humans do not have. While some cancers have prominent antigens that do not 
normally exist in our body such as BCR-ABL fusion protein in CML, the very 
existence of CML to begin with shows that just expression of an aberrant protein is not 
always enough to elicit a robust immune response [125]. To further use CML as an 
example, despite BCR-ABL fusion being a requirement for CML diagnosis and clearly 
related to malignancy, there are reports that a small amount of healthy individuals have 
this mutation in the normal population, suggesting that immune cells that recognize 
this fusion protein are indeed either absent or inactive in patients [126]. Evidence that 
the immune system can be activated to react against BCR-ABL was shown in recent 
experiments showing promising result in BCR-ABL vaccination capable of 
stimulating an immune response against BCR-ABL expressing cells [127, 128]. 
The difficulty in detecting clear PAMPs in often DAMPs rich cancer 
microenvironment can lead to further immune evasion through the function of 
regulatory cells. As mentioned previously, the phenotype of innate immune cells 
depends on their environmental context through binding on PRRs. As many tumour 
cells do not express clear PAMPs that are detectable in a pathogenic context by innate 
immune cells, the main stimuli they receive are that of DAMPs due to destructive 
tumour activity, and there are numerous studies that show these tumour associated 
macrophages (TAMs) as promoters of tumour growth, angiogenesis and drivers of 
metastasis [129-132]. The metabolic rate of cancers also leads to a hypoxic 
microenvironment as well as induce pH changes that further promotes angiogenesis 
due to secretion of Vascular Endothelial Growth Factor (VEGF) by pericytes as a 
response [133].  
Cancer cells are also able to convert local fibroblasts into cancer-associated fibroblasts 
(CAFs) through various stimuli such as cytokine stimulation and alternation of their 
extracellular matrix. This in turn aids cancer in both growth and immune evasion by 




Furthermore, there is ample amounts of evidence showing that many types of cancer 
attract Tregs through chemokines induced by the hypoxic microenvironment such as 
CCL12, CCL22 and CCL28 or directly secreted by the tumour cells themselves which 
leads to local immunosuppression through secretion of regulatory cytokines or 
expression of inhibitory surface molecules [136-138]. 
Additionally, it has been shown that some types of cancer such as malignant 
melanomas and non-small celled lung cancer directly inhibit effector immune cells by 
expressing inhibitory molecules such as PD-L1 [139, 140].  
1.3.3 Classical therapies for cancer and limitations 
Treatment for cancer has always been highly affected by the timing of diagnosis. By 
far the most successful and oldest method of therapy has been surgical resection with 
wide margins or complete removal of the affected organ if possible. The globally 
recognized standard of charting the progress of cancer is through the Tumour- Node-
Metastatsis Classification of Malignant Tumors (TNM) developed by the Union for 
International Cancer Control (UICC) (Figure 8). While different cancers have different 
















Tx Tumor cannot be evaluated 
T0 No evidence of a primary tumor 
T1-4 
a-b-c  
Refers to size of tumor  
Letters refer to specifics of different 
cancers 
Nearby lymph nodes 
Nx Nearby lymph nodes are not evaluated 
N0 No cancer cells are found in nearby 
lymph nodes 
N1, N2, N3 etc Cancer cells are found in the written 
amount of nearby lymph nodes 
Distant metastasis 
MX Metastasis cannot be measured  
M0 Cancer has not spread to other parts of 
the body 
M1 Cancer has spread to written amount of 
other parts of the body 
 
Figure 8. General criteria for the different TNM staging parameters.  
The figure illustrated how to interpret the three different main parameters of TNM 
staging classification as established by UICC. Figure created based on UICC 





While surgery is highly relevant in early stages of cancer and prognosis is usually 
good as long as the tumour has low TNM staging, once metastasis occurs the 
prognosis usually drops drastically, but to what degree depends on the cancer type and 
can be disputed depending on how cause of death is classified [142-144].] 
The traditional methods of treating metastatic cancer are by chemotherapy, which is an 
umbrella term for treatment with various drugs aimed at inhibiting growth processes 
such as mitosis. As uncontrolled growth is one of the hallmarks of cancers, inhibitors 
of mitosis were some of the first chemotherapy drugs used. This led to the 
development of anti-folates which inhibit de-novo DNA synthesis even though the 
mechanisms of action were unknown at that time [145]. Today the anti-folic drug 
methotrexate introduced in 1950 is one of the most widely used drugs in treatment of 
cancer and other conditions where reduction of proliferating cells are beneficial [146, 
147].  
Platinum-based chemotherapy is another example of chemotherapeutic drug targeting 
mitosis by inhibiting DNA replication. Most notably the drug cisplatin revolutionized 
the treatment of testicular cancer, which turned a 90% 1 year mortality rate pre-
cisplatin discovery into roughly 95% 10 year survival [148]. On other malignancies, 
the effects have been somewhat limited, and many studies show that cancer resistance 
towards the drug occurs rapidly. There are also severe side effects due to the toxicity 
induced by platinum-based chemotherapy [149-151]. Other widely used chemotherapy 
drugs include anti-microtubule agents and topoisomerase inhibitors which both also 
inhibit mitotic activity. 
A shared trait among many of the old widely used chemotherapeutic drugs is therefore 
their non-specific nature, as cell division, while being a hallmark of cancer, is by no 
means specific for malignant cells. Most notably healthy cells that require ample 
amounts of cell division include cells of the gastrointestinal tract and hair follicular 
cells. It is therefore no surprise that some of the most common side effects caused by 





The introduction of radiotherapy was enabled after the discovery of X-rays by Röntgen 
in 1895 and has been used as therapy against various cancers since then [154]. 
However, even with advances for over a hundred years, the limitations of radiotherapy 
remain largely the same. Similar to surgical resection, radiotherapy is unable to 
distinguish between healthy tissue and malignant tumours and relies on other methods 
such as imaging or staining techniques to determine treatment location. This means 
radiotherapy is often considered a supplementary treatment option such as reducing 
tumour size or burden before treatment with another more specific method, or as 
primary treatment with curative intention in non-metastatic cancers located where 
surgery is infeasible. It is also considered a staple of palliative management of late 
stage cancers. As radiotherapy inflicts considerable tissue damage to the treatment 
location, it is considered of limited use for curative intentions in metastatic cancer 
[155, 156].      
1.3.4 Prostate cancer  
The second most common cancer occurring in men and also the fifth leading cause of 
death worldwide is prostate cancer with 1,276,106 new cases and 358,989 deaths in 
2018 based on Global Cancer Observatory estimates [157]. While many low grade 
prostate cancers only require active surveillance, a subset of these patients develop 
metastatic prostate cancer which require intervention [158]. One of the main 
reasonings for why active surveillance is the modus operandi for prostate cancer 
around the world is due to the majority of cases being low grade that have limited 
benefit from treatment, the high incidence of the disease and side effects of treatment 
potentially being more detrimental than the progression of disease itself [159]. As 
prostate cancer is often discovered in elderly patients where surgical resection and 
extensive chemotherapy have considerable risk of complications, this factor is also 
taken into account when deciding treatment options [160]. 
For the patients who do develop metastatic prostate cancer, treatment options are often 
considered mainly life-prolonging rather than curative, and the progression of disease 




determining its androgen dependency. Many metastatic prostate cancer cells express 
androgen receptors which they rely upon for growth signals upon binding. Therefore, 
androgen deprivation hormonal therapy remains one of the first choice treatment 
options for metastatic prostate cancer [161, 162]. However, not all metastatic prostate 
cancers are androgen dependent, and usually even with androgen deprivation therapy, 
metastatic prostate cancer usually develop resistance over time. This is then usually 
referred to as castrate-resistant disease. Treatment of castrate-resistant disease usually 
involves anti-mitotic chemotherapy agents together with radiotherapy for palliative 
care [163, 164]. Due to the resistance developing nature of metastatic prostate cancer 
and the mainly life prolonging treatment options today, there is an urgent need for 
development of curative approaches for this patient group. 
1.4 Immunotherapy  
As we understand more of the hallmarks of cancer, it is evident that the traditional 
methods of surgical resection, mitosis inhibiting chemotherapy and radiotherapy have 
limited effect or severe side effects in treatment of metastatic cancer. While one 
approach to solve this problem is by simply improving early detection and increase 
chance of treating cancer in early TNM stages, the feasibility of this approach has its 
own limitations by sensitivity and specificity of diagnostic methods and the vast 
amount of different unspecific clinical manifestations [165-167]. As pre-metastatic 
detection for all cancer is currently unfeasible, better treatment options for metastatic 
cancer is still required. 
An ideal treatment for cancer would involve specific targeting of malignant cells with 
limited or no effect on healthy cells. As discussed previously the immune system has 
plenty of evidence both clinically and experimentally that it has the capability of 
mounting an immune response against cancers, and the methods in which cancer 
avoids detection by the immune system were also highlighted. Therefore, treatment 
options aimed at activating the immune system against metastatic cancer while 
suppressing the immune evasive capabilities of tumours is a promising aspect still 




One of the earliest documented attempts of inducing an immune response against 
cancer was conducted by Coley in 1891 but utilizing a bacterial vaccine consisting of 
heat killed bacteria in the treatment of inoperable sarcomas and reported a seemingly 
beneficial effect on survival for these patients [170]. While the concept of immune 
surveillance was proposed by Ehrlich in 1909, it took a long time before 
immunotherapy as a therapy for w-hen immunosurveillance fails re-emerged as a 
prominent topic in the treatment of cancer. A large contributing factor for this was due 
to the introduction of radiotherapy and the discovery of tumoricidal effects of chemical 
weapons used during world war I and II, notably mustard gas and its derivatives, 
which pioneered the development of the first chemotherapeutic drugs in use and 
became the “hot topic” for the latter half of the 20th century [171, 172]. During this 
period, onco-immunologists largely focused on stimulating and enhancing an immune 
response towards cancer with limited success. The first clinical trial with cytokine 
treatment utilizing IL-2 started in 1983 and ended with no increased immune reaction 
against cancer and only side effects in the patients involved [173].  
1.4.1 Dendritic cell immunotherapy 
The concept of using DC and their capability of inducing an adaptive immune 
response was pioneered by none other than one of the discoverers of these cells Ralph 
Steinman [174]. During his final years he was diagnosed with metastatic pancreatic 
adenocarcinoma in and decided to use himself as a case study for the potential of 
dendritic cell-based immunotherapy. Convincing his colleagues and collaborators, he 
was treated with RNA/peptide-loaded autologous dendritic cells in combination with 
chemotherapy, CTLA-4 checkpoint inhibitor and GVAX (GM-CSF-Gene-transduced 
allogeneic-irradiated pancreatic cancer cells). Sadly, he died just 3 days before 
posthumously being awarded the Nobel prize in medicine in 2011, but by then he had 
survived for four and a half years with a diagnosis that on average kills within a year 
and only about 1% 5 year survival rate [51, 175]. 
The potential of dendritic cells have shown great promise in animal models where 




specific CTLs and subsequent remission [176-178]. Dendritic cell based 
immunotherapy has also shown increased efficiency at eradicating tumours in mouse 
models when combined with checkpoint inhibitors [179].    
Clinical trials involving dendritic cell-based immunotherapies on humans, however, 
have shown limited efficacy. While there are some phase II trials showing 
improvement in outcome in metastatic melanoma, phase III trials have largely been 
inconclusive or ineffective in their outcome [180-182]. What all the clinical trials on 
DC based vaccines show, however, is that adverse events are limited, and the safety 
profile is high [183]. Furthermore, many of the trials have clear individual outliers 
with long term survival, suggesting that while statistically non-significant, it is likely 
that certain subgroups of patients could benefit greatly from DC immunotherapy. This 
phenomenon echoes the initial trial results of checkpoint-inhibitors, where overall 
increase in survival was modest, but certain individuals in the treatment group had 
long lasting progression free survival [184, 185]. DC based immunotherapy is also 
marred with lack of standardization between groups. Many trials vary in duration of 
vaccination, DC concentration of vaccination, location of administration and many 
other variables. This makes it difficult to compare the results of many of the clinical 
trials [186]. Other factors that might contribute to the disappointing results of moDC 
vaccine trials could be how response rate is defined. As many of the trials use 
statistical methodology from chemotherapy trials where patients often see results 
within weeks, the delayed but long lasting effect of immunotherapy that might take 
months and several sessions to work might be overlooked in those clinical trials and 
therefore new methods are in development to accurately measure the effect of delayed 
response rate [187].  
One of the main hurdles for utilizing DCs for therapy, is their accessibility. Shortly 
after the discovery of DCs 1973 and shown how potent they were at inducing an 
adaptive immune response [188], there were attempts of isolating DCs for the purpose 
of immunotherapy. One of the first feasible methods of getting adequate numbers of 
DCs in vitro was generating them from their hematopoietic progenitors identified by 




method was limited. It was not until 1994 that a method of generating DCs from 
monocytes was discovered by stimulating them with IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) to generate monocyte-derived DC 
(moDCs)[190]. This enabled generation of ample amounts of DCs from peripheral 
blood as around 10% of circulating PBMC comprise of monocytes. While there are 
some people who argue about the difference between conventional DC and moDC, 
there are studies that show moDC have comparable or even superior 
immunostimulatory effect [191].  
While moDCs have been shown to be able to trigger an immune response and have 
shown to be quite potent in vitro, as most clinical trials with moDC shows, there is 
room for improvement. As moDCs generated from monocytes by IL-4 and GM-CSF 
are immature, they only have a weak immunostimulatory effect on T-cells, they are 
not optimal for the purpose of immunotherapy [192]. Upon maturation, however, their 
immunostimulatory capabilities increase significantly, but what kind of immune 
response observed depends highly on the 3 signals conveyed to naïve T-cells [51].  
Mirroring the function of DCs in vivo, the context of how an antigen is taken up 
dictates much of the function of moDCs. This is affected by many factors, but some of 
the most important factors are the cytokines or stimulants used to mature moDC and 
the duration of stimuli [193-195]. Other factors such as what type of container used, 
and isolation method used for the moDC also affect their functionality [196].  The lack 
of standardization between laboratories working on moDC makes it difficult to 
compare many of the different findings and subsequently hard to determine if the low 
success rate of DC immunotherapy in clinical trials are due to patient conditions that 
makes treatment unfeasible, or if the DCs used were inadequate for their purpose. As 
we understand more about the maturation process of moDCs and the challenges of 
cancer however, it is evident that some of the more commonly used maturation 
processes are inadequate for immunotherapy. The common consensus nowadays is 
that CD8+ TILs are highly important as it is one of the biggest predictive factors for 
better prognosis, therefore moDC capable of inducing a robust CD8+ response are 




molecules and a cytokine profile that skews naïve T-cells towards development of 
tumour specific CTLs where among others, IL-12p70 is quite important [198]. 
One of the most popular maturation cocktails used was published in 1997 by Jonuleit 
et al and utilized a combination of IL-1β, IL-6, TNF-α and PGE2 (Jonuleit cocktail) 
and as the gold standard of the time, has been uses in many clinical trials [199]. As 
clinical trials continued to disappoint, however, people started investigating if there are 
problems with the moDCs generated. One of the major problems with the Jonuleit 
cocktail stimulated moDC was the low amount of IL-12p70 secreted which is vital for 
inducing a CD8+ response [200]. It later became apparent that PGE2 plays a 
paradoxical role when it comes to moDC maturation, as it provides a key signal to 
upregulate CCR7 in moDCs which triggers migration towards lymph nodes, but at the 
same time also downregulates their immunostimulatory abilities [201, 202]. There is 
also ample amount of evidence suggesting PGE2 to be an immunosuppressive cytokine 
in cancer as DAMP signal [203, 204]. Despite the limitations of PGE2, expression of 
CCR7 is absolutely crucial for dendritic cells in order to migrate to lymph nodes as 
several studies show that DC lacking expression of CCR7 fail migrate [205, 206].  
The limitations of the Jonuleit cocktail spurred the development of several other 
alternatives, such as interferon-based, TLR agonist based and 
polyinosinic:polycytidylic acid (Poly I:C) based ones that are currently being tested 
both in vitro and in clinical trials [200, 207, 208].  
Apart from to the generation method of the moDC, changing site of injection, 
increasing dosage or frequency of moDC vaccine, and/or addition of adjuvant therapy 
like IL-2 injection or chemotherapeutic drugs were investigated in hope of triggering 
an effective immune response against cancer [209-211].  
As limited success has been observed in DC based immunotherapy, postulations 
started regarding whether it was possible to skip the antigen presentation factor all 
together and instead directly alter T-cells to recognize known onco-antigens. With 
better techniques in gene transduction with viral vectors and more recently with the 
rising prominence of genome editing through clustered regulatory interspaced short 




has risen in prominence [212, 213]. One such method is the development of chimeric 
antigen receptor T-cells (CAR-T) which bypasses many of the tolerogenic challenges 
faced by normal T-cells by artificially inducing expression of TCR with an 
intracellular domain that leads to direct activation [214]. The nature of custom 
designing TCR to recognize cancer relies upon that the cancer has a known onco-
antigen, which is the reason why CAR-T was initially only approved for B-cell cancers 
as they often have specific markers such as CD19, CD20 and CD22 [215-217]. 
However, as often observed with cancer in many clinical trials, long lasting effect has 
been limited as selection pressure eventually leads to antigen escape by promoting 
malignant cells not expressing the targeted antigen [218].    
1.4.2 The rise of checkpoint inhibitors 
It was not until 2009 after the pioneering works of Allison and Honjo on their research 
on immunological checkpoint molecules that a paradigm shift occurred in the 
immunotherapeutic approach to cancer. People started to realize that attempting to 
force an immune reaction without considering the inhibitory factors had limited 
chance of success [219-221]. 
Several clinical trials investigating the effects of CTLA-4 and PD-1 inhibitors in 
treatment of metastatic melanoma were conducted in the early 2000s and the results 
had immediate impact upon the field of oncology. Compared to conventional 
chemotherapy, the long year survival rate of grade 4 metastatic melanoma patients 
improved between 10-20% to over 40% after treatment with various checkpoint 
inhibitors. A striking feature among the surviving patients is the reduced occurrence of 
relapse due to development of drug resistance that plagues traditional treatment 
options for this patient group and while traditional treatment often had severe side 
effects drastically reducing quality of life, checkpoint inhibitors often have milder side 
effects in comparison [221-224]. 
While melanoma was the first success story of check-point inhibitor treatment, clinical 
trials involving the use of checkpoint inhibitors in other cancers quickly followed with 




celled lung cancer and renal cancer where checkpoint inhibitors led to significant 
improvement in survival [225-227]. 
Since their rise to prominence, there are currently over a thousand clinical trials 
investigating the effect of checkpoint inhibitors on various metastatic cancers where 
most of them are combination therapies of various checkpoint inhibitors in 
combination with each other, or with targeted therapies, chemotherapies or 
radiotherapies [228, 229]. However, a clear trend is that monotherapy with checkpoint 
inhibitors does not yield the best survival rates, and that prognostic markers for which 
patients benefit from checkpoint inhibitor therapies are severely lacking [230]. While 
there are markers such as PD-L1 expression on tumour that in theory should be 
predictive for PD-1 and PD-L1 inhibition therapy, the predictive value is still low 
indicating that just inhibition of checkpoint molecules are insufficient in activating an 
immune response against cancer in many patients [231].   
A clear trend can be observed when it comes to what types of cancer checkpoint 
inhibitors are effective in. Tumour mutational burden (TMB) observed in tumours is 
clearly associated with beneficial effect of checkpoint inhibitor therapy [232-234]. It is 
likely due to increased chance for the immune system to detect tumour-specific 






Figure 9. Tumor mutational burden across several types of cancer 
The figure shows number of mutations compared to amount of neoantigens detected 
across several types of cancers (A) and the prevalence of somatic mutations across 
several types of cancer (B). The study by Büttner et al shows that high TMB highly 
correlates with the two cancers responding most to checkpoint inhibitors being 
NSCLC and melanoma. Figure from Büttner et al, 2019 [233]. Reprinted with 






1.4.3 OK432 in immunotherapy 
The concept of using pathogenic components to stimulate the immune system is still 
widely researched today, and strikingly similar to Coley’s work in 1891, an 
immunostimulatory drug comprising of freeze-dried Streptococcus pyogenes named 
OK432 was approved in 1975 in Japan after earlier studies conducted by Okamoto et 
al found anti-cancer activity in haemolytic streptococci [235]. OK432 is currently one 
of the primary drugs of choice for unresectable lymphatic haemangioma after Ogita et 
al reported remarkable shrinkage of tumour in over 90% of paediatric patients [236]. 
As the only side effects appears to be slight fever in a minority of the patients, the drug 
quickly became a common adjuvant for various ailments in Japan. With the emergence 
of moDC for immunotherapy, Japanese researchers were quick to postulate the 
potential of OK432 in stimulating these cells and early research indicated that OK432 
matured moDC could induce tumor specific CTLs [237]. Further research a decade 
later by Hovden et al investigated the mechanisms of how OK432 stimulated moDC 
and found out it partially acted as a TLR3 agonist and managed to stimulate moDCs 
into secreting IL-12p70. The main issue with OK432 matured moDCs though was the 
lack of chemotaxis as they had negligible expression of CCR7 [238, 239].      
1.4.4 Challenges of immunotherapy 
As discussed previously, while there is potential for DC based immunotherapy and 
both in vitro and animal studies have shown great promise, it is evident by the clinical 
trials there are many challenges facing not just DC based immunotherapy, but 
immunotherapy in general. 
As demonstrated clearly by clinical trials involving immunotherapy of various forms, 
there is a high degree of individual variation on what patients benefit from therapy. A 
flaw of the common nomenclature is that cancer is an umbrella term for ailments with 
similar clinical features, but it does not necessarily translate well into immunology as 
cancer subtypes and heterogeneity differ considerably when it comes to tumour 
specific antigen expression, tumour microenvironment and direct effect on the immune 




By investigating the effect of various cancers on the immune system, a more precise 
decision can be made on determining what cancers immunotherapy have higher 
likelihood to work on. As covered earlier, mutational burden of the cancer type 
correlates with the outcome of immunotherapy, but for clinical trials the average age 
of included individuals likely plays a role. It is a well-known fact that immune 
impairment is more prevalent with age and as most cancers are heavily associated with 
age, many individuals might have limited benefit from immunotherapy [242]. It has 
also been shown that for many cancers, moDC generated from patients have impaired 
functions [243, 244]. Shinde et al reported several distinct properties regarding moDC 
generated from multiple myeloma patients when compared to healthy controls. While 
antigen-uptake ability and T cell stimulatory ability was similar to that of healthy 
controls, moDC from multiple myeloma patients had lower viability, impaired CCR7 
expression and altered cytokine profile [243].   
Another challenge for immunotherapy is the ethical decisions surrounding inclusion 
criteria for clinical trials. In theory, DC based immunotherapy has more benefit the 
earlier it is introduced as to promote the elimination phase of the three Es and 
minimize the risk of prolonged Equilibrium state and subsequent Escape despite 
treatment. However, as experimental treatments in general only get approved for 
patients where all other options have been exhausted, many patients included have had 
anti-mitotic chemotherapy which impairs the immune system and hampers the effect 
of immunotherapy long after treatment end [245, 246]. 
Other precautions are that of side effects. While as mentioned more or less all the 
clinical trials investigating moDC therapies have been shown to have minimal side 
effects, as shown by trials combining CTLA-4 inhibitor and PD-1 inhibitor, therapies 
that are well tolerated by monotherapies can quickly become detrimental once 
combined without adequately assessing therapeutic windows [247, 248].While animal 
models have been useful as safety screening for many different drugs, their use for 




1.4.5 Challenges of immunotherapy in prostate cancer 
While immunotherapy in the form of checkpoint inhibitors has become a huge success 
in cancers like melanoma and non-small celled lung cancer, checkpoint inhibitors have 
had limited success in prostate cancer trials [249]. There are many factors that make 
prostate cancer challenging for the immune system. Compared to many other cancers, 
prostate cancer has relatively low mutagenic burden and limited expression of cancer 
specific antigens. In addition, metastatic prostate cancer appears to have strong 
capability of transforming local fibroblasts into CAFs and skew local macrophages 
into M2 phenotype [250, 251]. While immunotherapy might appear bleak for such 
conditions, there have been reported case studies where immunotherapy appears to 
work [252]. There are also clinical trials investigating DC-based immunotherapy 
efficacy in metastatic prostate cancer where integrity of the immune system is a 
prognostic factor and trials where similarly to initial results using checkpoint inhibitors 
in other cancers, see a subset of patients that appear to have long term benefits after 
immunotherapy [253, 254]. These findings do suggest that while difficult, 













2. Aims    
The overall aim of the project was to increase our understanding of how different 
culture conditions affect moDC and the potential of OK432 as a maturation stimulus.  
The specific aims were: 
1: To investigate how OK432 in combination with other compounds affects maturation 
and T cell stimulatory capacity of moDCs compared to the gold standard at that time, 
the Jonuleit cocktail  
2: To investigate how culture dish surfaces with different adherence properties affect 
moDC properties regarding phenotype and functionality  
3: To investigate if the OK432 based stimulation cocktail is applicable on cells from 
metastatic prostate cancer patients . 
 
 













3. Material and methods 
 
3.1 Cohort information 
The project was conducted according to the Declaration of Helsinki. All anonymised 
biological material in the form of buffy coats used for paper I was collected at the 
Blood Bank of the Haukeland University Hospital after written informed consent was 
collected. As the study was a technical and methodological development work that 
used anonymised biological material, no approval from the regional ethical committee 
was required.  
 
For paper II, freshly drawn peripheral blood was collected from 19 healthy volunteers 
into BD Vacutainer ACD-A 10 ml citrate tubes (BD, Franklin Lakes, USA). Informed 
consent was obtained from all donors. Informed consent was gathered from all donors 
and approved by the regional ethical committee Western Norway (REK Vest; 
#2009/686). 
 
In paper III, monocytes were isolated by elutriation from leukapheresis preparations of 
6 prostate cancer patients included in the clinical trial (Clinical.trials.gov. ACT2001 -
NCT02423928; EudraCT Number: 2014-001898-14) in a certified Good 
Manufacturing practices (GMP) grade lab at The Section of Cell Therapy (Oslo 
University Hospital, Oslo; Norway). The study was approved by the Norwegian 
Regional Ethical Committee (REK #64205; REK#2014/1052). 
3.2 Blood collection, PBMC and monocyte isolation and cryopreservation 
PBMCs were separated by density gradient centrifugation (Lymphoprep™, Axis-
Shield, Norway). Monocytes were then isolated using plastic adherence, which utilizes 
monocytes’ tendency to stick to plastic surfaces to separate them from non-adherent 
cells (NACs) (Paper I & III). For certain experiments fresh blood collected from 
healthy volunteers were collected in BD Vacutainer ACD-A 10 ml citrate tubes (BD, 




Monocytes were then separated by negative isolation with Monocyte Isolation Kit II 
(Miltenyi Biotec Norden AB, Lund, Sweden) which utilizes antibody coated magnetic 
beads binding to non-monocyte PBMCs running through a magnetic funnel. In 4 of the 
experiments, anti-CD-61 microbeads (Miltenyi Biotec Norden AB, Lund, Sweden) 
were also added to reduce platelets (Paper II). DCs were frozen in some of the 
experiments in X-vivo 20 medium (Lonza) with 10% DMSO in Mr. Frosty freezing 
containers (both Sigma-Aldrich) at -80 °C (Paper I & III).  
3.3 Cell culture, DC generation and maturation 
In paper I, moDCs were generated by culturing isolated monocytes in RPMI 1640 
(Lonza) with 10% FCS, 100 units/ml penicillin, 100µg/ml streptomycin, IL-4 (20 
ng/ml) and GM-CSF (100 ng/ml) (both ImmunoTools, Friesoythe, Germany) at 
37 °C and 5% CO2 humidified atmosphere in adherent cell culture plates (Nunclon Δ, 
Thermo Fischer Scientific, USA; Paper I).  
In paper II, moDCs were generated by culturing isolated monocytes in CellGro DC 
medium (CellGenix) in both adherent and non-adherent culture plates (Nunclon 
Hydrocell & Nuncleon Sphera, Thermo Fischer Scientific, USA). In paper I and paper 
II, the cells were cultured for 3 days with replenishment of IL-4 and GM-CSF on day 
2, while in paper III, thawed moDCs from prostate cancer patients were cultured in 
Cellgro DC medium in same concentration of IL-4 and GM-CSF for two days. One 
hour prior to maturation stimuli, 1 µg/ml tuberculin-purified protein derivate (PPD, 
Statens Serum Institut, Denmark) was used as recall antigen (Paper I & II & III) before 
stimulation with various stimulation cocktails as shown in table 1. As all blood was 
collected from residents in Norway who had mandatory Bacillus Calmette-Guèrin 
Vaccine (BCG) vaccination from 1948-1994 and all donors/patients were in that age 
group, PPD was deemed fit as recall antigen [255]. After maturation, moDCs were 
used for co-culture or for analysis on an LSRFortessa (BD Biosciences) flow 
cytometer.  





Cocktail name Content Paper 
Jonuleit cocktail IL-1β (10 ng/ml, Immunotools) 
IL-6 (1000 U/ml, Immunotools) 
TNF-α (10 ng/ml, Immunotools) 
PGE2 (1 µg/ml, Sigma-Aldrich) 
I & II 
LPS LPS (100 ng/mg, Sigma-Aldrich) II & III 
OK432  OK432 (0.1 KE/ml, Chugai Pharmaceutical Co. Ltd) I 
OK432 + CL097 OK432 (0.1 KE/ml) 
CL097 (1 µg/ml, Invivogen) 
I 
OK432 cocktail OK432 (0.1KE/ml) 
CL097 (1 µg/ml) 
PGE2 (0.5 µg/ml) 
 
I & III 
Lövgren cocktail TNF-α (10 ng/ml) 
IFN-γ (1000 U/ml, Sigma Aldrich) 
R848 (2.5 µg/ml, Invivogen) 
PolyI:C (20µg/ml, Sigma Aldrich) 
I & III 
Kalinski cocktail TNF-α (50 ng/ml) 
IL-1β (25 ng/ml) 
IFN-α (3000 U/ml, Immunotools) 
IFN-γ (1000 U/ml) 
PolyI:C (20µg/ml) 
I 
Zobywalski cocktail TNF-α (10 ng/ml) 
IL-1β (10 ng/ml) 
IFN-γ (5000 U/ml) 
PGE2 (0.25 µg/ml) 
R848 (1 µg/ml) 
PolyI:C (20 ng/ml) 
I 
IL-10 IL-10 (10 ng/ml; Immunotools) II 
DexVD3 Dexamethasone (1 µM; Sigma Aldrich) 
1α, 25-Dihydroxyvitamin D3 (VD3) (1 nM; Enzo Life 
sciences) 
II 





3.4 Blocking antibodies 
In paper II, blocking antibodies against CD11a, CD11b, CD11c, CD18 or E-cadherin 
(all 10µg/ml; Invitrongen/Thermo Fisher, USA) were added to moDC culture during 
generation to investigate the effect of those surface molecules on cell to cell and cell to 
culture dish adhesion. Morphology was analysed by light microscopy using a Cytation 
5 Cell imaging-reader (BioTek instruments). 
3.5 moDC – NACs co-culture 
In paper I and II, mixed leukocyte reaction (MLR) co-culture was performed. After 
generation of moDC, co-cultures with either autologous or allogeneic NACs were 
setup in X-vivo 20 medium with addition of IL-2 (50 U/ml) and IL-7 (10 ng/ml; both 
Immunotools) in Nunclon Δ well plates and incubated at 37 °C and 5% CO2 humidified 
atmosphere for 5-7 days. Some of the NACs were labelled with carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE; Invitrogen) according to manufacturer’s 
instructions (papers I & II). After culturing, the NACs were used for IFNγ secretion 
assay and/or analysis on an LSR Fortessa or Accuri C6 (BD Biosciences) flow 
cytometer. 
MLR is a method to measure T-cell proliferation capacity of moDC through co-
culture. In an allogeneic co-culture, the MHC molecule will be recognized as foreign 
and trigger clonal expansion of recipient T-cells, but in autologous co-culture, clonal 
expansion is not triggered without a stimulatory antigen presented by the APCs 





Figure 10. Allogeneic mixed leukocyte reaction 
Antigen presenting cells of donor allogeneic peripheral blood lymphocytes (PBL) have 
their MHC molecules (blue) recognized by recipient T-cells triggering activation and 
proliferation (A), but autologous MHC does not get recognized by recipient T-cells 
and no activation or proliferation occurs (B). Figure from The Immune response: 
basic and clinical principles, T. Mak and M. Saunders, [256], modified with 
permission from Wolters Kluwer Health, Inc. 
3.6 Flow cytometry 
To analyse the phenotype of the generated moDCs and induced T-cells, flow 
cytometry was utilized. Flow cytometry is a commonly used tool both in research and 
clinic to measure and analyse large amounts of cells and other particles in a suspension 
an accurate manner. The strength of the method lies in its ability to measure multiple 
features on an individual particle in a heterogenous mixture. Flow cytometry utilizes 
hydrodynamic focusing to force particles to pass in a single file through the laser 
beam. Particles are generally labelled with fluorochrome-attached antibodies or 




The light scatter from the laser beam hitting the particle or fluorescence emitted by 
excited fluorochromes is converted into electronic signals by photomultiplier tubes 
(PMTs). These electronic signals from each particle can then be analysed. The use of 
multiple lasers and optical filters allows excitation and detection of emission at 
different wavelengths for the identification of different fluorochromes and hence 
targets (cell receptors etc.) by their unique excitation and emission spectra 
simultaneously. Expression levels of targets can then be quantified, or alternatively the 
combination of identified features can be used to identify cell subsets.  A typical flow 
cytometry setup for moDC is shown in figure 11. Fluorochrome panel design and 
protocols were determined by study purpose and antibodies were titrated to minimise 
non-specific staining. While one or two study specific markers were included or 
excluded, in general the analysed markers comprise of signal 1 marker HLA-DR, 
signal 2 markers CD80, CD83 and CD40, maturation marker CD83, chemokine 
receptor CCR7 and checkpoint markers PD-L1 and PD-L2 with some additions 
depending on the study [238, 257-259]. The whole list of markers used is shown in 









Figure 11. Typical flow cytometry experiment on moDC isolated by plastic adherence.  
PBMC can be isolated through density gradient centrifugation with Ficoll and 
cryopreserved or cultured. On adhesive surface conditions, monocytes will adhere to 
culture container at 37 °C, 5% CO2 humidified atmosphere while NACS will remain 
suspended. The monocytes can then be generated into moDC with or without 
maturation stimuli. The resulting moDC can then be co-cultured with NACs or stained 
and analysed. NACs after co-culture with moDC can also be stained and analysed.  
The flow cytometer is setup to optimize detection of individual fluorochromes and 
minimize run-to-run variation by adjusting voltages of PMTs. Analysis is subsequently 
performed by various software available, spectral overlaps of fluorochromes are 
corrected (compensation) and cell subtypes are identified by their antigen expression 
indicated by their respective fluorochrome in a process called gating. Figure inspired 









Table 2. Monoclonal antibodies with fluorophores used for moDC panel in the 
different projects 
Fluorochrome  Surface marker Clone Used in paper 
FITC CD14 18D11 I + II + III 
PE CD1a HI149 I + II + III 
PE-Cy7 CD40 5C3 I + II + III 
Alexa Fluor 647 CD86 IT2.2 I + II + III  
Brilliant Violet 421 CCR7 G045H7 I + II + III  
PE-CF594 CD83 HB15e I + II + III  
Horizon V500 HLA-DR G46-6 I + II + III  
Brilliant Violet 605 CD80 2D10 I + II 
PerCP-Cy5.5 CD38 HIT2 I + II 
FITC CD18 TS1/18 II 
PerCP-Cy5.5 CD11c 3.9 II 
APC-Cy7 HLA-A,B,C W6/32 II 
PE-Cy7 PD-L1 MIH1 II 
Alexa Fluor 647 PD-L2 MIH14 II 
Brilliant Violet 421 CD11b ICRF44 II 
Brillivant Violet 785 CD80 2D10 III 
Brilliant Violet 711 PD-L1 29E,2A3 III 
APC-Cy7 PD-L2 MIH18 III 














Table 3. Monoclonal antibodies with fluorophores used for T-cell panel in paper III 
Fluorochrome  Antibody clone 
AF488 CD20 2H7 
AF488 CD56 NCAM1 
PerCP-Cy5.5  CD8 RPA-T8 
PE  CD28 CD28.2 
PE-Cy7  CD127 A019D5 
PE/Dazzle594  CD137 4B4-1 
APC-Cy7  CD4 RPA-T4 
AF700  CD3 UCHT1 
APC  CCR7 G043H7 
BV785  CD45RO UCHL1 
BV605 CD45RA HI100 
BV650  CD25 BC96 
BV421 CTLA-4  BNI3 
BV711 CCR5 3A9 
BV510 PD1 EH12.2H7 
 
 
3.7 Chemotaxis assay 
In paper I, moDCs were added to the upper chamber of an 8µm transwell membrane 
96-well plate (Corning Lifesciences) and left to migrate towards CCL19 (100 ng/ml, 
Immunotools), a ligand of CCR7, in X-vivo 20 medium for 4 h at 37 °C, 5% 
CO2 humidified atmosphere before quantification with a CASY cell counter (Roche) 
which uses a low voltage field across a medium to detect cell size by electric 
resistance. As membranes act as electric insulators, detection pores in the machine 
registers the resistance encountered by the electric field to measure the size of cells. As 
dead cells are often either very small or have broken membrane integrity, their signals 
are considerably smaller than those of living cells. The method can also be used to 




3.8 IFN-γ secretion assay 
Analysis of T-cell activity by measuring their IFN- γ secretion was performed in all 
papers. After 7 days moDCs and NACs co-culture with or without 5 days resting 
period, some NACs were isolated and cultured with mature autologous moDCs with or 
without PPD loaded for 16 hours in X-vivo 20 at 37 °C, 5% CO2. The IFN-γ secretion 
was then measured using an assay kit (Miltenyi Biotec). The method utilizes 
conjugated antibodies bound to surface molecules on T-cells with a receptor for IFN- γ 
which it catches upon secretion by its bound cell. The caught IFN-γ is then bound by a 
detection antibody with fluorochrome attached and subsequently analysed on a flow 
cytometer. CD4 and CD8 antibodies were used to distinguish the cells from each 
other. T-cells stimulated with Staphylococal enterotoxin B from Staphylococcus 
aureus (SEB), a superantigen, was used as positive control, while co-cultures with 
moDC without PPD loaded was used as negative control.   
3.10 ELISA (Paper I) 
Cell culture supernatant was stored at -20 °C. To quantify IL-12p70 and IL-10 
secretion into the supernatant, sandwich enzyme-linked immunosorbent assays 
(ELISA; BioLegend) were utilized according to the manufacturer’s instructions. The 
samples were run in technical duplicates to reduce variability. The concept uses a 
capture antibody coated on a well plate and subsequent binding with a biotinylated 
detection antibody. Horseradish peroxidase (HRP) is then added to form an Avidin-
Biotin complex which reacts with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate 
which in turn results in a measurable colorimetric reaction that can be quantified by a 
microplate reader. Concentrations of antigen in medium are determined by comparing 






3.11 Luminex assay 
Cytokine and chemokine concentrations from culture supernatant after moDC 
maturation were determined using a 25-plex Luminex assay cytokine and chemokine 
panel (Invitrogen, catalogue number LHC0009) and run on a Luminex 100 System 
(Luminex Corporation, Austin, TX) according to the manufacturer’s instructions 
(Paper I & II). 
The method utilizes polystyrene beads with unique tagged fluorochromes, biotinylated 
antibodies and Steptavidin/Phyocerythrin to detect cytokines or chemokines. Similar to 
ELISA, the concentrations are then calculated from a standard curve.  
3.12 Data analysis 
Visualization and analysis of flow cytometry data was done using Flowjo (Tree Star). 
Identification of cell subsets were done using light scatter properties in combination 
with expression levels of different receptors, and various controls including unstained 
cells and Fluorescence Minus One (FMO). Statistical analysis of measurements was 
performed in Prism 5 (Graphpad). Significance between samples were tested using 
Kruskal-Wallis one-way analysis of variance (ANOVA) test (paper I & III) or 2way 
ANOVA test (paper II) with Dunn’s post-test (paper I & II & III) or Bonferroni post-
test (paper II). All statistical formulas and post-tests used are for non-parametric 
analysis due to individual variation of the immune system and the low amount of study 











4. Summary of the main results 
Paper I 
Different maturation stimuli comprising of, OK432 alone, OK432 + CL097 and 
OK432 cocktail were tested on the generation of moDC from healthy donor donors 
and was compared to the Jonuleit cocktail. Surface molecules HLA-DR, CD83, CD1a, 
CD80, CD86, C40, CD38, CCR7 and CD14 were measured by flow cytometry to 
determine phenotype. All cells showed high expression of HLA-DR. All maturation 
cocktail stimulated cells showed increased maturation marker CD83 compared to 
unstimulated control, and high expression of co-stimulatory molecules CD80 and 
CD86. OK432 stimulated cells had low expression of CCR7 but was elevated above 
expression by Jonuleit stimulated cells with the addition of CL097 and PGE2. OK432 
cocktail was also the most capable of inducing CD80 and CCR7 among the cocktails 
tested. 
Migration assay showed increased migratory capacity by moDCs stimulated with 
PGE2, and almost no migratory activity was seen in moDCs matured without PGE2. 
Jonuleit matured moDCs showed highest amount of transwell migration while OK432 
cocktail matured moDCs had around half as much but significantly higher than 
controls. 
To measure cytokines, Luminex multiplex analysis of 26 different cytokines was 
performed. All OK432-matured DCs had a significant increase in IL-12p70 secretion 
compared to Jonuleit cocktail and immature control that was further elevated with the 
addition of CL097 but decreased by PGE2. This pattern was also observed with 
RANTES/CCL5, MIP-1α/CCL3, and MIP-1β /CCL4. IL-12p40 was highly elevated 
by OK432 cocktail, but not statistically significant compared to the other matured DC 
populations. IL-10 secretion was detected at low levels. IL-8 secretion was 
significantly reduced by the addition of OK432. IL-7 was increased in every matured 
DC population. IL-17 secretion was increased by OK432 alone but decreased with the 
addition of CL097 or PGE2. IL-16, IL-1RA, IFN-γ, IFN-α, MCP-1, IL-2R, and IL-13 




IL-13, or Eotaxin was secreted at very low levels while IL-4, GM-CSF, IL-1β, IL-6, 
and TNF were excluded from the analysis as they were used in the culture media.  
MLR was performed to investigate T-cell stimulatory capacity. OK432 stimulated 
moDCs were superior to Jonuleit cocktail stimulated moDCs at inducing T-cell 
proliferation with OK432 cocktail stimulated moDCs being the most potent.  IFN-γ 
assay was used to determine antigen-specificity of those expanded cells and showed 
that while OK432 cocktail stimulated moDCs were able to induce antigen-specific T-
cells, it was not significantly more than Jonuleit cocktail stimulated moDCs.  
To compare OK432 based maturation stimuli with other more recent maturation 
cocktails, an IL-12p70 ELISA was performed on moDCs stimulated by Jonuleit 
cocktail, OK432 + CL097, OK432 cocktail, Kalinski cocktail, Lövgren cocktail and 
Zobywalski cocktail. All cocktails induced higher IL-12p70 secretion compared to 
Jonuleit cocktail with Lövgren cocktail inducing significantly higher secretion than the 
rest. OK432 based cocktails induced similar level of IL-12p70 secretion to the other 
cocktails otherwise. 
Paper II 
The effect of surface adherence on the generation of moDC was investigated by 
comparing generation on standard cell culture dishes and non-adherent culture dishes. 
Two immunogenic conditions comprising of LPS and Jonuleit cocktail stimulated 
moDC and two tolerogenic conditions comprising of IL-10 and DexVD3 stimulated 
moDC were tested on the different surfaces. 
In all conditions generated on non-adherent surface culture dishes, homotypic 
clustering could be observed by light microscopy. Several blocking antibodies were 
tested against known molecules associated with adhesion, CD11a, CD11b, CD11c, 
CD18 and E-cadherin. Blocking CD18 resulted in reduced homotypic clustering while 
blocking CD11a or CD11b appeared to promote homotypic clustering. 
Phenotype under the four different conditions was investigated by flow cytometry with 
a panel of 15 different surface molecules. The results showed that all surface 




checkpoint molecule PD-L1 was decreased on moDCs stimulated with the Jonuleit 
cocktail in a non-adherent culture dish while PD-L2 was increased. The differences 
were noted to depend both on culture dish adherence and stimuli. 
Cytokine production was investigated using a 25-plex Luminex platform and showed 
cytokine production varied depending on the treatment and the surface used. In 
general, LPS-DC had the highest production of most cytokines. Most cytokines were 
overall secreted at lower levels on non-adherent surface. While the cytokine profile of 
the DC cultured in tolerogenic conditions as well as control showed limited differences 
in cytokine profile regardless of culture dish surface, the LPS stimulated DCs had 
significant profile differences. IL-10 and TNF-α secretion was increased in all LPS 
stimulated DCs on standard cell culture dish compared to non-adherent surface, while 
the opposite was true for IL-15 and MIG.  
In order to investigate the possibility that isolation impurities might have an impact on 
the clustering, phenotype, and cytokine production, four of the monocyte isolation 
procedures were performed using additional anti-CD61 beads to remove platelets. 
Both the phenotype of the generated DC populations and their produced cytokines did 
not show any clear differences between the preparations with and without residual 
platelets 
Lastly, the T cell stimulatory capacity of the generated moDC populations was 
analysed in an allogeneic MLR. No obvious differences were observed between the 
different surfaces, regardless of the DC population used as stimulator. The 
proliferation of monocyte-depleted PBMC co-cultured with the tolerogenic moDC 
populations was less than with immature DC. The immunogenic moDC populations 
was further analysed in an autologous setting with an IFN-γ assay. Both LPS- and 
Jonuleit-cocktail stimulated cells were able to induce antigen specific autologous 
CD4+ and CD8+ T cells, with slightly higher numbers of IFN-γ producing T cells 







To investigate the potential of OK432 cocktail matured moDC on T-cells from cancer 
patients, moDCs were collected from patients with metastatic prostate cancer and 
stimulated with either OK432 cocktail, Lövgren cocktail or left untreated as negative 
control. Phenotype of moDC was investigated using a panel of 11 different surface 
markers. All analysed moDC populations yielded phenotypically mature DC with high 
expression of MHC class II, co-stimulatory molecules CD40, CD80 and CD86, and moderate 
expression of maturation marker CD83 including the negative control. Checkpoint molecules 
PD-L1 and PD-L2 were also highly expressed. In contrast to paper I, using moDC from 
healthy donors, the addition of PGE2 in the cytokine cocktail did not positively affect CCR7 
expression.  
Phenotypic analysis with a 15-marker panel showed that T-cells co-cultured with the OK432 
cocktail stimulated moDC for 7 days significantly increased the proportion of 
CD25+/CD45RO+ cells among both CD4+ and CD8+ cells. This population was also 
relatively low in CD127 expression. No significant difference was observed in checkpoint 
molecules CTLA-1 or PD-1.   
IFN-γ secretion assay was used to investigate antigen-specific T-cell activity, but large 
interindividual variations and low number of samples make significance hard to interpret. 
However, IFN-γ secretion by T-cells was increased after stimulus by PPD loaded moDC 
compared to stimulus with moDC without PPD loaded in all samples suggesting that it is 












5.1 Methodological considerations  
5.1.1 Culture, treatment and storage condition of cells 
Many laboratory and logistical methods can influence the phenotype of PBMCs and 
their behaviour. This has been shown in several studies where investigators found out 
that PBMC varied considerably depending on factors such as storage time, storage 
concentration, whether it is whole blood or buffy coats, temperature, workflow and 
cryopreservation [261]. 
In particular, yield after cryopreservation differs considerably between methods, but 
just higher viability does not necessarily mean best preservation method as there are 
studies showing that freezing medium can significantly alter the cell functions [262]. 
Generated moDCs are no exception to this as shown in an earlier study [263].  
Medium used for cell culture in vitro is considerably different than in vivo. Conditions 
such as natural physiological changes, cell to cell communication, physical and 
chemical conditions are all altered. It is known that too high or too low concentration 
of cell culture can affect cell functions [264].  
Culture duration was also a consideration during our study design. Different groups 
often use different protocols on how long monocytes should be cultured with IL-4 and 
GM-CSF and how often the cytokines should be replenished [200, 265, 266]. In our 
group we determined on preliminary results that after 3 days, the cells had drastically 
reduced CD14 expression, a monocyte marker, and highly elevated HLA-DR and 
CD1a used as markers for moDC differentiation which is in line with a study by 
Schendel et al [266].   
While working with cells, mechanical stress from centrifugation, pipetting and 
temperature differences can lead to cell apoptosis or necrosis and yields in the various 
experiments varied considerably. Many immune-cells are naturally sensitive to such 
conditions due to having DAMP receptors and can be stimulated to secrete various 




samples, practically it is not possible as the samples themselves are not equal in terms 
of concentration upon sampling, stickiness in the case of monocyte adherence, and 
other factors. However, if the differences are large enough, conclusions can be drawn 
even with slight margins of error. 
5.1.2  Considerations in moDC stimulation 
As one of the main investigative aims of the project, OK432 with its TLR3 stimulatory 
capability along with other factors was considered a prime candidate for moDC 
stimulation in cancer immunotherapy. The rationale behind utilizing OK432 over a 
TLR3 ligand is due to the nature of what OK432 is, which are freeze dried 
Streptococcus particles, which means it can stimulate immune cells more than just in a 
TLR3 dependent manner. The hope is that OK432 can stimulate immune cells into 
interpreting cancer antigens as pathogenic by proxy. Due to the long history of OK432 
used clinically in Japan as adjuvant for various cancers, it has shown to be a safe 
substance to inject into humans, and by extension cells cultured with it.  
The addition of CL097, also known as Imidazoquinoline, as an TLR7/8 agonist was to 
improve the immunogenic stimuli on moDC further. As it has been used in 
dermatological products since 1997 where the first Imidazoquinoline creams were 
approved by the FDA and its safety profile is well known as a skin product [268].   
5.1.3 Special considerations on MLR 
In several of our experiments we used MLR to measure T-cell stimulatory capacity. To 
investigate the T-cells ability to undergo clonal expansion, PPD was picked as recall 
antigen. Due to Norway’s vaccination programme, it is to be expected that donors 
have memory cells specific for PPD, and therefore proliferate upon successful 
presentation by APC. This gives valuable information about the quality and properties 
of the APCs but does not represent presentation of cancer neoantigen and ability to 
react towards that. As knowledge about choice of cancer antigens is limited and patient 
availability is limited, investigating the APC properties of moDC on a recall antigen 




The nature of MLRs also might affect the analysis as proliferation means conditions 
are not constant in each population. Notably we had to change medium and replenish 
cytokines to avoid apoptosis by lack of survival stimuli. While the fewer proliferating 
samples were treated at the same time as the highly proliferating samples, what effect 
the temporary reduction in survival cytokines and nutrients had is unknown.         
5.1.4 Special considerations on flow cytometry 
In flow cytometry, there are some error potentials that are hard to avoid. To keep cells 
in a single file by hydrodynamic focusing, the speed of acquisition matters 
considerably. Too high acquisition speed leads to risk of doublets, which means two 
cells passing the laser at the same time and resulting in data error. While this can be 
mitigated to some degree with adjusting the speed and good gating, it does lead to 
some slight error. The staining procedure can be time sensitive as fluorochromes 
naturally loses fluorescence when exposed to light. This can be mitigated to some 
extent by keeping the stained samples away from or blocking light, but not always 
feasible. The choice of fluorescent antibodies and the concentration of the staining 
procedure also matters greatly. Titration of antibodies and adjustment of voltages prior 
to analysis are crucial for accurate measurement of data. For paper III this became an 
issue as patient samples were very limited and varied, therefore titration was done on 
blood from healthy donors which had some differences. This becomes more complex 
the more fluorochromes included as there are limits to the span of the electromagnet 
spectrum and fluorochromes that can fit in a single panel. When two fluorochromes 
are close to each other on the electromagnetic spectrum, overlap can occur. This is 
something we encountered with some of our fluorochromes, and some concessions had 
to be made to reduce spillover. Limiting spillover is a fine balance between adequate 
separation between positive and negative signals as too high signal usually means 
more spillover, while too low signal means it becomes difficult to separate positive 
from negative. Mitigating spillover requires compensation, which is a mathematical 
method of subtracting overlap signals from the respective channels, but it depends 
heavily on the quality of positive and negative controls, autofluorescence of cells and 




for fluorochrome compensation and unstained cells for autofluorescence 
compensation, but slight differences can still be made in compensation calculation. 
The choice of staining condition also matters as binding happens faster in higher 
temperature due to thermodynamic activity. However, higher temperature leads to 
more internalization of surface receptors in T-cells which can affect the analysis. 
Therefore, we stained T-cells for 30 minutes on ice while moDCs were stained in 
room temperature for 10 minutes. As dendritic cells are sufficiently large that they 
appear as a clear population compared to debris and other cells in forward scatter and 
side scatter plots in flow cytometry, gating around them is not a difficult task as dying 
or dead cells are clearly smaller. This is harder to gate around regarding T-cells which 
are smaller and therefore harder to separate from debris and dead cells. Therefore, we 
used Pacific Orange as a live-dead stain. 
5.1.5 Special considerations on migration assay 
For chemotaxis assay, transwell methods, while easy to setup, have limited relevance 
physiologically as concentration of target chemoattractant differs from physiological 
response and the static nature of wells hardly represent the vascular or lymphatic 
system. While it does convey information about cells ability to migrate through a 
membrane, how reflective it is of behaviour in vivo is highly debatable [270]. The 
choice of using a CASY cell counter was also due to feasibility, but as the purpose was 
to show that the cells could migrate and controls were not supposed to migrate at all, 
the slight variance in counting was deemed of little relevant. 
5.1.6 Special considerations on IFNγ assay 
Measurement of T-cell using an IFN-γ based assay is a reliable way of detecting the 
number of activated T-cells. Several studies show that antigen-specific T-cells indeed 
starts secreting IFN-γ upon activation [271-273]. The ratio between moDCs and T-
cells are quite important for this measurement, and while the start ratio is similar for 
all samples, the end ratio can differ based on individual variations due to apoptosis or 
proliferation which in turn can affect the results, but this is likely not significant due to 




binding to cells can affect them to some degree, but according to the developers of this 
method it has no negative impact on the cells [273, 274]. 
5.1.7 Special considerations on ELISA  
For ELISA, the concentration of cytokines frozen from supernatant is influenced by 
the number of cells in the culture. As individual variation is observed when it comes to 
viability during the generation of moDC and subsequent yield of them, it is no surprise 
that total cytokine profile of the culture will be affected. As we are comparing 
maturation treatment of moDC, there should be variations on how immune cells of 
individuals react to the different cocktails and subsequently affect the total cytokine 
profile. We can therefore only report how the treatment acts upon the cells as a group 
rather than how it affects individual cells. To correct for this, results from both ELISA 
and Luminex are compared to viability data during cell harvesting. As proteins 
degrade over time and with increased temperature and ELISA is a lengthy procedure, 
some loss is to be expected during the processing even if being kept on ice for as long 
as possible [275]. Many of the same limitations can be applied to Luminex assays as 
well.  
5.1.8 Special considerations on statistical analysis 
For statistical analysis, the methods picked are appropriate for the studies. However, 
due to the low number of included samples it can be difficult to interpret. Outliers can 
heavily skew the grand mean and can mainly be mitigated by larger sample size which 
is not always possible due to cost or available study population. While trends can be 
observed even with small sample sizes, one should be careful to draw conclusions 
even with statistical significance.  
5.2 Implications of research results 
As clinical trials using moDC show that results are varied and often negative in 
immunotherapy, and generation methods of moDC vary considerably between labs, 
investigating what influences the generation process becomes crucial. While steps 
towards better reproducibility and standardisation is underway with fully automated 




to such equipment is currently limited. While generation of immature moDC is 
generally agreed upon to rely on the method established by Sallusto and Lanzavecchia 
in 1994 [190], this is not the case for maturation methods. For a long period of time, 
the maturation cocktail developed by Jonuleit et al has been used for many clinical 
trials but was deemed insufficient for the purpose of immunotherapy. As referred to 
previously, many groups have developed their own cocktails for the maturation 
process of moDC, and how the blood/PBMC is processed and stored also vary 
significantly. As there is no standard on how to mature moDC for the purpose of 
immunotherapy, we set out to investigate potential new cocktails and other factors and 
compare them to that of other protocols. As CCR7 expression and migration to lymph 
node are crucial for adaptive immune response, our focus was finding a cocktail that 
both induced CCR7 expression in moDC as well as immunogenic phenotype. As our 
studies have shown, moDCs are heavily affected by various factors that might be 
overlooked normally during generation and therefore explain many of the variable 
results seen in the clinical trials. The burst of excitement generated by the success of 
checkpoint inhibitors and how it mainly works in specific cancer types and subset of 
patients has spurred numerous clinical trials on the basis that the methodology is not at 
fault, but rather the target population. Many of the clinical trials with moDC has 
followed the same philosophy with disappointing results. Hopefully our research can 
contribute to better understanding and possible standardization on moDC generation 
methodology. 
5.2.1 The role of OK432 in moDC maturation and the effects of PGE2 
As one of our goals was to determine OK432 matured moDC as candidate for 
immunotherapy, the properties of the OK432 matured moDC had to be compared to 
the gold standard at the time and prominent cocktails used by other groups [199-201, 
207]. As our results show, the cells have properties that are desired for immunotherapy 
which are high expression of HLA-DR, costimulatory molecules CD80 and CD86 and 




The main problem for OK432 matured moDC as described previously by Hovden et al 
[238], was the lack of CCR7 expression which meant that moDC matured only with 
OK432 would in theory not migrate towards lymph nodes and therefore have limited 
clinical value. As the Jonuleit cocktail managed to mature moDC with high expression 
of CCR7 but limited immunogenic properties, several groups started investigating 
which component in the cocktail contributed to this phenomenon. It was subsequently 
determined that PGE2 was crucial for CCR7 expression in moDC but was also 
immunosuppressive [202, 204]. As CCR7 expression is crucial for DC migration to 
lymph nodes, we hypothesized that the stimulatory and inhibitory functions of PGE2 
might be concentration dependent and that the Jonuleit cocktail used too much of it. 
Strikingly in paper I, we observed that migratory capability was almost linearly 
correlated with the amount of PGE2 added to the maturation cocktail. The results of 
our finding support the notion that PGE2 is a key up-regulator of CCR7 for moDC. 
Why this apparent paradox role exist requires further research, but it might play a role 
in local inflammatory homeostasis. As shown by Hangai et al [204], PGE2 is released 
by apoptotic cells which in turn inhibits inflammatory conditions. This could mean 
that PGE2 in high concentration acts as a DAMP and that DCs might mature with more 
tolerogenic properties without adequate PAMP stimuli. This is in line with what we 
know about macrophages who change phenotype towards immunosuppressive and 
regulatory M2 phenotype in the presence of PGE2 [276]. A clinical support for this 
hypothesis is observed in pregnancy, an immunosuppressive state, where serum PGE2 
is elevated [277].  
The main notable difference between OK432 matured moDC compared to Jonuleit 
cocktail matured moDC was in their cytokine profile, which showed that OK432 
matured moDC had a much more promising profile. The high secretion of IL12p70 is 
already a good indicator, but interestingly one of the most obvious differences was 
observed in IL-8 which was significantly reduced for every sample included. Initially 
as this was part of the 25 Luminex panel, it was not deemed one of the cytokines of 
interest, but subsequent investigation into literature showed that elevated IL-8 is 




Furthermore IL-8 is a chemokine that mainly attracts neutrophils, which in turn might 
have a negative effect for the purpose of immunotherapy as neutrophil infiltration in 
tumours appears to be a negative prognostic marker in contrast to CD8+ TILs [120, 
279]. This negative role is supported by observations that recruitment of neutrophils to 
lymph nodes can have an inhibitory effect on the adaptive immune response in cancers 
[280]. Therefore, the observed low IL-8 secretion by OK432 moDC appears to be a 
positive trait for the purpose of immunotherapy. It should also be noted that all OK432 
matured moDC had elevated IL-12p70 and IL-12p40 compared to Jonuleit cocktail 
matured moDC. The addition of CL097 appeared to increase IL-12p70 with OK432, 
but did not affect secretion of IL-12p40 suggesting CL097 to primarily be an 
proinflammatory stimuli. The addition of PGE2 significantly increased secretion of IL-
12p40 when added onto OK432 with CL097 but also resulted in less IL-12p70. This 
suggests that PGE2 might be partially responsible for inactivating IL-12p70 into its 
inactive form IL-12p40. 
5.2.2 Cell culture surface should not be ignored 
Commonly observed in many papers involving cell culture, the flasks and containers 
used for culture are not stated. It has often been taken for granted that in vitro 
conditions are reflective on in vitro conditions. The established process of erythrocyte 
and plasma transfusion and the safety profile of those clinical methods add to the 
notion that cells do not change significantly during transport or processing. In fact 
procedures such as freezing plasma for transfusion are considered safe, and for 
military personnel, frozen erythrocytes are also in for clinical use [281, 282]. This 
however might be limited by the functions of the components as erythrocytes and 
platelets have limited role outside of their primary functions. As the immune cells are 
highly sensitive to their environment and have drastic different functions depending on 
the context of what they detect, the same assumptions cannot be made. It is known that 
immune cells have homing and anchoring capabilities such as macrophages to specific 
tissues, and that they have stretch sensitive cellular components that alter their 
functions [283-285]. It is not hard to imagine that the adherence of cell surfaces can 




In paper II, we showed that adherence plays a significant role in how moDC mature 
under different stimuli. Interestingly homotypic clusters could be observed in all 
conditions without adhesion to plate surfaces and this persisted for days, suggesting 
that monocytes and moDC actively seek adherence to other cells or surfaces. We also 
showed that blocking CD18 drastically reduced this phenomenon while blocking 
CD1a and CD1b increased the homotypic clustering which resulted in the hypothesis 
that CD1a and CD1b might act as a competitive inhibitor to the adhesive functions of 
CD18 which is in line with a study by Sàndor et al [286]. 
In addition, we showed that cell phenotype of generated moDC is also affected by 
culture surface conditions especially in inflammatory conditions. Possible explanations 
to this might be due to the contextual nature of immune cells in general, as cells often 
use adhesion signals to contextualize their location and surroundings. Monocytes do 
not normally reside in tissue, but are instead circulating in the bloodstream or in the 
spleen and differentiate into other cells once migrated into other tissues [287]. 
Therefore, it is sensible that their differentiation status differs whether they are 
attached to a surface or not. How cell to cell adhesion affects their differentiation 
function, however, remains to be seen as we have yet to investigate the effects of 
CD18 blockage on moDC generation. There is also a possibility that the changes 
observed are due to conditions within the clusters as in cancer, the centre of tumours 
often have necrotic conditions due to lack of access to nutrients [288]. 
For the purpose of immunotherapy, the culture dish surface appears to depend on what 
stimuli used as we saw different effects of surface adhesion with different stimulation 
conditions. What simulates in vivo conditions better is also questionable as immature 
DC reside in tissue awaiting stimuli, whereas mature DC loses anchoring properties to 
local tissue and migrate towards lymph nodes. Therefore physiologically speaking 
during generation, monocytes should technically be in non-adherent culture dishes 
with fluidic movement to simulate blood flow and switched to adherent culture dishes 
once generated into immature moDC, but this is logistically not very feasible. The 




regarding culture dish used and be mindful about data interpretation depending on 
culture dish used. 
5.2.3 Challenges with studying cells from cancer patients  
It is a well-known fact that cancer patients often have altered immune systems 
compared to healthy individuals [289]. As we found OK432 cocktail matured moDC 
to have properties that appeared beneficial for immunotherapy, we wanted to 
investigate whether moDC from prostate cancer patients reacted similar to healthy 
controls with the same treatment. There were however notable challenges due to 
various factors. Firstly, moDC for the purpose of immunotherapy requires a certified 
GMO grade lab for generation which is not available at our location, therefore patient 
PBMCs had to be shipped to Oslo for generation and shipped back. The cells were 
cryopreserved in liquid nitrogen, but this adds a factor which we did not have in our 
previous OK432 matured moDC studies. Additionally, considerable amount of 
apoptosis was observed in the cells once thawed and it is impossible to determine what 
role logistics played as no healthy control samples were sent parallel with the prostate 
cancer patient samples. 
As generation of GMO grade moDC for therapeutic purposes was very expensive, 
there were limitations to how many samples we could obtain, and combined with the 
considerable cell loss after thawing, meant that there were restrictions on how many 
samples could be run (paper III). Our results, however, showed that moDCs from 
prostate cancer patients showed fairly similar mature phenotype regardless whether 
they were stimulated by a maturation cocktail or not, suggesting processes during 
generation of immature moDC or aftercare resulted in a mature phenotype. It is known 
that cryopreservation can activate immature moDC [263], but choices were limited 
without a local GMP grade lab. Ideally there should be no cryopreservation or delay 
between collection of patients PBMC and generation of moDC for therapeutic 
purposes, but logistically this is not currently possible.  
Regardless of the lack of differences observed in the moDC phenotype of prostate 




L2. The T-cells stimulated also showed high expression of PD-1 on the majority of 
CD4+ and CD8+ cells, suggesting that immunotherapy on these patients likely benefit 
from checkpoint inhibitors. Whether this is a property of prostate cancer patients, 
however, is not answerable in our study as we do not have healthy controls included in 
the logistics portion of the study. However, our study is in line with some observations 
by another study that show increased PD-1 expression by T-cells in prostate cancer 
patients [290].    
The expansion of CD25+ memory cells by OK432 cocktail matured moDC in prostate 
cancer patients is interesting, but what it indicates is somewhat questionable. As 
OK432 contains components of Streptococcus pyogenes, a very common bacteria, it 
should come as no surprise that memory cells are activated if moDC present these 
antigens. We did use PPD as a recall antigen and PPD antigen specific IFN-γ response 
was observed regardless of moDC treatment, but as only 3 patients were included with 
















The challenges and results from the three studies included in this thesis highlight the 
complex nature of moDC generation and how easily monocytes are affected by various 
factors that are often overlooked. Future studies on applicability of moDC for 
immunotherapy should take into consideration of those factors when developing their 
protocols. 
OK432 matured moDCs show promising aspects for immunotherapy due to phenotype 
with high expression of HLA-DR, CD83, CD80, CD86 and most importantly, the lack 
of CCR7 expression was remedied with the addition of PGE2 in the cocktail with 
limited immunosuppressive effect. IL-12p70 secretion by moDC was further increased 
with the addition of CL097. The functionality of the CCR7 expression was confirmed 
by transwell assay. T-cell response could be induced by OK432 cocktail matured 
moDC and IL-12p70 secretion by OK432 cocktail matured moDC was comparable to 
many other maturation cocktails.  
Surface adhesion properties of culture dishes highly impact the phenotype and 
cytokine profile of generated moDC in many ways that vary depending on culture 
condition. It is highly suggested future studies take these considerations into account 
and always include details about culture conditions apart from medium and stimulants. 
Logistical considerations should be considered when designing moDC studies. Patient 
materials might not be as readily available, and cryopreservation needs to be evaluated 
for feasibility regarding moDC for immunotherapy. T-cells from metastatic prostate 










7. Future perspectives  
 
While we have done many preliminary studies on the potential of OK432 as a 
maturation stimulus for moDC, more remains to be done regarding their feasibility for 
immunotherapy. The results from paper I revealed some interesting features that 
should be taken into consideration. Notably the cytokine profile of OK432 cocktail 
matured moDC having reduced IL-8 should be investigated whether it is functional or 
not. It might be interesting to conduct a migration assay to check autologous 
neutrophil chemotaxis towards these moDCs compared to those matured by the 
Jonuleit cocktail.  
The findings regarding PGE2 are particularly interesting as while its effect on 
chemotaxis has been confirmed by other studies to be relevant, limited studies have 
been done on the effect of different concentrations of PGE2 on migratory capability of 
moDC [201, 291]. 
Apart from the significant findings in paper I, the number of samples are on the low 
side, so more repetitions are always welcome to clarify some of the results. 
Additionally, as we have revealed in paper II, different stimuli affect cells differently 
depending on cell culture surface. Therefore, it might be interesting to investigate 
OK432 cocktail matured moDC compared with Jonuleit cocktail matured moDC in 
different culture surface conditions as that was observed regarding Jonuleit cocktail 
and LPS stimulated moDC. 
The findings of paper II also suggest that reconsiderations need to be highlighted 
among immunologists regarding the culture containers used as clearly monocytes react 
differently to surface adhesion than many other cells. Additionally, it would be 
interesting to see whether these changes are concentration dependent as clearly the 
cells in non-adherent surface containers formed homotypic clusters and the density of 
the clustering effect itself might contribute to the changes observed. As we revealed 
CD18 to be the main contributor to the clustering effect, what role CD18 plays in 




as potential competitive inhibitors. It would also be interesting to see if blocking CD18 
affects cells generated in standard cell culture dish surfaces. 
Finally, the study conducted in paper III did not meet its goal of determining whether 
moDC generated from metastatic prostate cancer patients could benefit from OK432 
cocktail stimulation because control for the logistics part of the study was not 
included. This makes it impossible to determine if changes observed are due to 
processes such as cryopreservation, handling and delay or properties associated with 
the disease. Therefore, future studies should ideally avoid factors that might influence 
the results and always include controls undergoing the same treatment.  
What did differ in paper III, however, is that there appears to be a clear expansion of 
CD25+ memory T cells by OK432 cocktail stimulated moDC. While we did use PPD 
as recall antigen, it remains to be seen if OK432 stimulated moDC also expand CD25+ 
cells in the absence of recall antigen and could be investigated in the future. 
The final key message of our findings is the necessity to include checkpoint inhibitors 
when using moDC for immunotherapy. High expression of checkpoint molecules was 
observed in both paper II and paper III regardless of moDC treatment, therefore it is 
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Monocyte-derived dendritic cells (moDC) are an important scientific and clinical source
of functional dendritic cells (DC). However, the optimization of the generation process
has to date mainly been limited to the variation of soluble factors. In this study, we
investigated the impact of the cell culture dish surface on phenotype and cytokine
profile. We compared a standard cell culture dish to a non-adherent culture dish for two
immunogenic maturation conditions, two tolerogenic conditions, and an unstimulated
control. Phenotype, cytokine profile and T cell stimulatory capacity were determined after
a 3-day culture. Light microscopy revealed an increase in homotypic cluster formation
correlated with the use of non-adherent surfaces, which could be reduced by using
blocking antibodies against CD18. All surface markers analyzed showed moderate
to strong differences depending on the culture dish surface, including significantly
decreased expression of key maturation markers such as CD80, CD86, and CCR7
as well as PD-L1 on cells stimulated with the Jonuleit cytokine cocktail cultured on a
non-adherent surface. Significant differences in the secretion of many cytokines were
observed, especially for cells stimulated with LPS, with over 10-fold decreased secretion
of IL-10, IL12-p40, and TNF-α from the cells cultured on the non-adherent surface. All
immunogenic moDC populations showed similar capacity to induce antigen-specific T
cells. These results provide evidence that the DC phenotype depends on the surface
used during moDC generation. This has important implications for the optimization of
DC-based immunotherapy development and underlines that the local surrounding can
interfere with the final DC population beyond the soluble factors.
Keywords: homotypic clusters, monocytes, monocyte-derived dendritic cells, immunogen, tolerogen, adhesion,
non-adherent culture plate, cytokines
INTRODUCTION
Dendritic cells (DC), positioned between the innate and adaptive immune system, play a central
role in a great variety of immunological settings. They play an important role for the pathogenesis
of many diseases, and are increasingly also under investigation as a clinical tool to treat a great
diversity of different challenging conditions, ranging from cancer to autoimmunity (1). The role
of DC in medicine has already been highlighted by their discoverer Ralph M. Steinman (1, 2),
Sauter et al. DC Affected by Local Surroundings
ranging from infectious diseases over autoimmunity to cancer
(3–5). However, the complexity of the pathogenic settings in
the immune system and the diversity of DC subtypes are
contributing to an enduring challenge to understand and apply
DC biology. Many obstacles have to be overcome on the way
to clinics, but the understanding of the in vitro system for
the development of DC applications is of special importance.
As DC are a central sensing unit collecting all information
before a possible activation of the adaptive immune system,
it is not surprising that the culturing environment can have
a great impact on the cellular phenotype and thus on the
induced immune response. Commonly, blood monocytes are the
major source of cells to generate DC ex vivo, mainly because
they are readily accessible. Monocyte-derived DC (moDC) are
then generated by use of conditioning soluble factors, usually a
combination of GM-CSF and IL-4, to induce the DC program
in monocytes, followed by a maturation cocktail that mimics an
in vivo maturation condition leading to the desired phenotype.
For example, one of the commonly used maturation cocktails for
immunogenic DC is one that imitates an inflammatory situation
in the skin (referred to as “Jonuleit cocktail”), containing IL-1β,
IL-6, TNF, and prostaglandin E2 (PGE2) (6). Moreover, serum-
free formulations are recommended to ensure reproducibility
and achieve compliance with clinical requirements (7). However,
only the impact of soluble factors is commonly considered, the
adhesional culture properties are hugely ignored in most in vitro
protocols. If mentioned at all, standard cell culture plates are
recommended. Alone the in vivo regulation of DC adhesion upon
maturation (8, 9) gives an indication that adhesional signaling
might be of importance in a potentially more diverse way than
can be expected from an unspecific surface of a plastic cell culture
dish. In connection with the culturing conditions, we observed an
early increase in DCmarkers on immature DC when cultured on
non-adherent surfaces compared to standard cell culture dishes
(10). In the same study, we observed an increase in homotypic
clustering of the cells on non-adherent surfaces compared to
cells on standard cell culture plates. Thus, the choice of the
culture dish can potentially have a significant impact on the DC
phenotype and function by either supporting the early, integrin-
mediated adhesion followed by low homotypic clustering, or
by reducing culture dish interactions leading to an increase in
clustering and thus cluster-mediated cell-cell interactions.
The aim of the present study was to investigate the
effect of the culture dish surface on the phenotype and the
cytokine production of differentially stimulated immunogenic
and tolerogenic moDC populations. We found that both
phenotype and cytokine secretion are modulated in a treatment-
dependent manner. Moreover, using blocking antibodies, we




Freshly drawn peripheral blood was collected from 19 healthy
volunteers into BD Vacutainer ACD-A 10ml citrate tubes (BD,
Franklin Lakes, USA). Informed consent was obtained from
all donors. The study was approved by the regional ethical
committee Western Norway (REK Vest; #2009/686). The age of
the donors was ranging from 23 to 67 years. Monocytes were
isolated as described previously (10). In short, peripheral blood
mononuclear cells (PBMC) were isolated by density gradient
centrifugation using Lymphoprep (Axis- Shield, Oslo, Norway).
The PBMC were washed twice and centrifuged at 220 g for
8min at 4◦C, respectively, in order to further increase the
leukocyte to platelet ratio. Monocytes were further isolated
using the Monocyte Isolation Kit II (Miltenyi Biotec Norden
AB, Lund, Sweden). In four experiments, additional anti-CD61
microbeads (Miltenyi Biotec Norden AB, Lund, Sweden) were
added to reduce residual platelet numbers. The final untouched
monocyte fraction was washed, counted on a CASY cell counter
and resuspended in serum free CellGro DC medium (CellGenix
GmbH, Freiburg, Germany). During culture, Nunclon 1 6-
well plates and Nunc HydroCell 6-well plates were used in
comparison as representative standard culture dish and non-
adherent culture dish, respectively (Thermo Fisher Scientific,
Waltham, USA). For the MLR and the blocking antibody
experiments, the non-adherent culture dish was changed to Nunc
Sphera (Thermo Fisher Scientific, Waltham, USA), the newer
line of non-adherent culture plates, due to discontinuation of
the HydroCell series. 0.75 × 106 monocytes/ml CellGro DC
medium were plated per surface and per maturation stimulus,
supplemented with IL-4 (20 ng/ml) and GM-CSF (100 ng/ml)
(ImmunoTools, Friesoythe, Germany). IL-4 and GM-CSF were
replenished after 2 days, 24 h before cell harvesting.
For 5 of the donors, blocking experiments were performed.
For the other 14 donors, five different DC populations were
generated for each surface, two of them immunogenic (LPS
and Jonuleit cytokine cocktail, respectively), two tolerogenic
(Dex/VD3 and IL-10, respectively) and one control sample
without additional stimulus. LPS (100 ng/ml; Sigma-Aldrich,
Taufkirchen, Germany) and the Jonuleit cytokine cocktail
[10 ng/ml of IL-1β, 10 ng/ml of TNF, 1,000 U/ml of IL-
6; all ImmunoTools, Friesoythe, Germany, and 1µg/ml of
prostaglandin E2 (PGE2); SigmaAldrich, Taufkirchen, Germany]
were added 24 h before harvesting, respectively. For the
generation of DexVD3 DC, 1µM of dexamethasone (Dex;
Sigma- Aldrich, Taufkirchen, Germany) was added at the start
of culture, and replenished 24 h before harvesting together
with 1 nM of 1α, 25-Dihydroxyvitamin D3 (VD3) (Enzo Life
Sciences, Farmingdale, NY). For the generation of IL-10 DC,
IL-10 (10 ng/ml) was added at culture start and replenished
24 h before harvesting (Miltenyi Biotec Norden AB, Lund,
Sweden). As DMSO (Sigma-Aldrich, Taufkirchen, Germany)
was used as a solvent for Dex and VD3, a corresponding
amount of DMSO was added to the control samples (DMSO
iDC). All cells were harvested after 3 days in culture. Cell-
free supernatants were stored at −20◦C for later cytokine
detection. The remaining cells were washed off the surfaces
with PBS (without magnesium and calcium; Lonza, Verviers,
Belgium) containing 2mM EDTA (Sigma- Aldrich, Taufkirchen,
Germany). The viability of the generated DC population for
each condition was determined by annexin-V and 7-AAD
staining using the Annexin V Apoptosis Detection Kit (eFluor
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450) from eBioscience (AH Diagnostics, Oslo, Norway) and a
LSRFortessa cell analyzer (BD, Franklin Lakes, USA) located at
the Core facility for Flow cytometry, Dept. of Clinical Science,
University of Bergen.
Blocking Antibodies
In some experiments, blocking antibodies against CD11a (clone
HI111), CD11b (clone ICRF44), CD11c (clone 3.9), CD18
(clone TS1/18; all 10µg/ml; BioLegend, San Diego, CA, USA),
or E-cadherin (clone HECD-1; 10µg/ml; Invitrogen/Thermo
Fisher, Waltham, MA, USA), all low endotoxin, azide free,
were added in the growth medium for 3 days during moDC
generation. As a control, the moDC were cultured with mouse
IgG1 (BioRad, Hercules, CA, USA) supplemented in the growth
medium in the same concentrations as the blocking antibodies.
A cell population with no additional antibodies served as
a negative control. After 3 days of culture, the morphology
of the generated moDC populations was analyzed by light
microscopy using a Cytation 5 Cell imaging-reader (BioTek
instruments,Winooski, VT, USA), before the cells were harvested
for phenotyping.
Immunostaining
The phenotype of the generated moDC populations was analyzed
using the surface markers shown in Table 1. Cells were pre-
incubated for 5min using 2 µl of FcR blocking reagent (Miltenyi
Biotec Norden AB, Lund, Sweden) per up to 106 cells in 150 µl
cold PBS containing 0.5 % bovine serum albumin (BSA; Sigma-
Aldrich, Taufkirchen, Germany), followed by an incubation with
the titrated amounts of antibodies for 15min in the same buffer.
The flow cytometry analysis was performed at the Core facility for
Flow cytometry, Dept. of Clinical Science, University of Bergen,
using a BD LSRFortessa cell analyzer.
TABLE 1 | Mouse monoclonal anti-human antibodies with fluorophores and clone







CD86 Alexa Fluor 647 IT2.2
CD80 Brilliant violet 605 2D10
HLA-DR Horizon V500 G46-6




CD274 (PD-L1) PE-Cy7 MIH1
CD273 (PD-L2) Alexa Fluor 647 MIH14
CD11b Brilliant violet 421 ICRF44
Cytokine Detection
For the detection of cytokines in the cell medium after DC
generation, we used a magnetic microbead based 25-plex
human cytokine kit for the Luminex platform (Invitrogen
Corp., Carlsbad, USA). The cytokines measured were IL-
1β, IL-10, IFN-α, IL-6, IL-12, RANTES (CCL5), Eotaxin
(CCL11), IL-13, IL-15, IL-17, MIP-1α (CCL3), GM-CSF, MIP-
1β (CCL4), MCP-1 (CCL2), IL-5, IFN-γ, TNF-α, IL1RA, IL-
2, IL-7, IP-10 (CXCL10), IL-2R, MIG (CXCL9), IL-4, and IL-
8. All supernatants were thawed and analyzed simultaneously.
Measured median fluorescence intensity (MFI) values below the
standard-curve were set to the detection limit and cytokines
withMFI-values above the standard-curve were approximated by
extrapolating linearly.
Mixed Leukocyte Reaction (MLR)
In order to analyze the T cell stimulatory capacity of the
generated moDC populations, we performed allogeneic mixed
leukocyte reactions (MLR) as described previously (11). 5
× 104 moDC were co-cultured with 2 × 105 monocyte
depleted PBMC stained with CFDA-SE (Vybrant CFDA-SE
Cell Tracer Kit, Thermo Fisher Scientific, Waltham, USA)
for 5–7 days in X-Vivo20 medium supplemented with IL-7
(10 ng/ml) and IL-2 (50 U/ml; both ImmunoTools, Friesoythe,
Germany). At least 30,000 events were collected on a BD
Accuri C6 instrument at the Core facility for Flow cytometry,
University of Bergen.
IFN-γ Secretion Assay
An IFN-γ secretion assay (Miltenyi Biotec, catalog number
130-054-202) was utilized to analyze the capacity of the
generated DC populations to induce antigen specific T cell
responses as described previously (11). In short, 2.5 × 106
autologous monocyte-depleted PBMC were co-cultured with
5 × 105 PPD-loaded DC populations for 7 days in X-
Vivo20 medium supplemented with IL-7 (10 ng/ml) and IL-
2 (50 U/ml). The IFN-γ secretion assay was performed
according to the manufacturer’s manual. As stimulators, PPD-
loaded DC stimulated with LPS were used, and unloaded
LPS-DC served as negative control. 2 × 105 DC were co-
cultured with 8 × 105 induced monocyte-depleted PBMC
for 16 h. Staphylococal enterotoxin B from Staphylococcus
aureus (SEB; 1µg/ml; Sigma-Aldrich) was added as positive
control. Prior acquisition on a BD LSR Fortessa, the cells
were stained with anti-CD4 FITC (M-T466, Miltenyi Biotec)
and anti-CD8-APC (RPA-T8, Biolegend), as well as 7-AAD
(ebioscience). A minimum of 2 × 105 events were collected
in the Lymphocyte gate. FlowJo was used to analyze the data,
and % IFN producing cells were calculated according to the
following formula:
% IFNγ producing cells among CD4+ =
# of IFNγ+ CD4+ cells in the sample
# of total CD4+ cells in the sample
× 100
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IFN-γ producing CD8+ T cells were calculated accordingly. The
% IFN-γ producing cells from DC without PPD was subtracted
from the values with PPD.
Statistical Analysis
The statistical analyses were performed with Graph-Pad Prism
(v5.02). Statistical significance was determined by comparing the
cells of the two different surfaces for each treatment using a 2way
ANOVA test in combination with the Bonferroni post-test or
Dunn’s post-test, significance criterion<0.05. Significance values
in figures are given in grades P < 0.05 (∗), P < 0.01 (∗∗), and
P < 0.001 (∗∗∗). Median values for each surface and treatment
are marked with a line. Measured values are given as the mean±
the standard deviation (SD) if not stated otherwise.
RESULTS
The Lack of Surface Adherence Leads to
Increased Homotypic Cluster Formation
That Can Be Reduced by Blocking CD18
Using light microscopy, we observed an increase in cell
cluster formation on the non-adherent culture dish in
comparison to the standard cell culture dish for all moDC
populations (Figure 1, Figure S1). Considerably smaller
clusters were also observed on the standard cell culture
dish, especially for the immunogenic stimulation conditions
with LPS or the Jonuleit cocktail (Figure S1). Viability was
not influenced by the different surfaces (data not shown).
In order to determine the molecules responsible for this
clustering behavior, we added various blocking antibodies
to the culture. Blocking CD18 reduced clustering on the
non-adherent plates (Figure S2), while blocking CD11a and
CD11b appeared to promote homotypic clustering, independent
of the surface used. Blocking CD11c and E-cadherin had
inconsistent results.
Culture Dish Adherence Influences
Phenotype and Cytokine Production of
moDC
We further investigated phenotypic differences depending on the
treatment and surface conditions by analyzing expression levels
of 15 different surface markers using flow cytometry (Figure 2).
The expression of all cell surface molecules was influenced by
the culture dish used. Interestingly, the use of a non-adherent
culture dish decreased expression of PD-L1 on cells treated with
the Jonuleit cocktail, while the other PD-ligand, PD-L2 (CD273),
was highly expressed.
Cytokine production varied depending on the treatment and
the surface used (Figure 3). In general, LPS-DC had the highest
production of most cytokines. Regarding the influence of the
culture dish surface, most cytokines were overall secreted at
lower levels on non-adherent surface. Interestingly, the levels of
exogenously added cytokines GM-CSF and IL-4 varied a lot. GM-
CSF levels were higher on the standard cell culture dish than on
the non-adherent surface, while IL-4 levels were lower. While
the cytokine profile of the DC cultured in tolerogenic conditions
as well as control showed limited differences in cytokine profile
regardless of culture dish surface, the LPS stimulated DCs had
significant profile differences. Interestingly, IL-10 and TNF-α
secretion was increased in all LPS stimulated DCs on standard
cell culture dish compared to non-adherent surface, while the
opposite was true for IL-15 and MIG.
Blocking of adhesion molecules resulted in little differences in
surface expression of most markers analyzed (data no shown).
Additional Platelet Reduction During
Monocyte Isolation Has No Distinct Effect
on Phyenotype and Cytokine Production
In order to investigate the possibility that isolation impurities
might have an impact on the clustering, phenotype, and cytokine
production, four of the monocyte isolation procedures were
FIGURE 1 | Homotypic cell clusters form on the non-adherent surface but less on the standard culture dish. Representative microscopy pictures of iDC (DMSO) at the
end of the 3-day culture on (A) a standard cell culture dish and (B) a non-adherent culture dish. The increase in cell cluster formation on non-adherent dishes relative
to standard dishes could be observed for all treatments (n = 8).
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FIGURE 2 | Influence of the culture dish on the phenotype of differentially stimulated moDC. The phenotype was analyzed by flow cytometry using the indicated
surface molecules. % positive cells or median fluorescence intensity (MFI) are shown. Color code: Control (DMSO)—green, immunogenic DC populations (LPS &
Jonuleit cytokine cocktail)—red, tolerogenic DC populations (Dexamethasone with vitamin D3 & IL-10)—blue. Squares (left): standard culture dish; circles (right):
non-adherent culture dish. The median is marked with a line. Significance values are given in grades *P < 0.05, **P < 0.01, and ***P < 0.001. Black significance
grades are the result of a collective 2 way ANOVA testing for all treatments, red grades are from separate tests for the iDC/tolDC and immunogen subgroups (n = 8).
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FIGURE 3 | Influence of the culture dish on the cytokine production of differentially stimulated moDC. Cytokines were measured in cell free culture supernatants of the
generated moDC populations. Color code: Control (DMSO)—green, immunogenic DC populations (LPS and Jonuleit cytokine cocktail, respectively)—red, tolerogenic
DC populations (Dexamethasone with vitamin D3 and IL-10, respectively)—blue. Circles (left): standard culture dish; squares (right): non-adherent culture dish. The
median is marked with a line. Significance values are given in grades *P < 0.05, **P < 0.01, and ***P < 0.001. Black significance grades are the result of a collective 2
way ANOVA testing for all treatments, red grades are from separate tests for the iDC/tolDC and immunogen subgroups (n = 6).
performed using additional anti-CD61 beads to remove platelets.
While the monocyte purity without the use of anti-CD61 beads
was >85 %, it increased to >95 % when additional anti-CD61
beads were used (Figure S3), confirming that platelets were the
main impurity. However, both the phenotype of the generated
DC populations and their produced cytokines did not show
any clear differences between the preparations with and without
residual platelets (data not shown).
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The Cell Culture Surface Does Not
Influence the T Cell Stimulatory Capacity
of moDC
Lastly, we analyzed the T cell stimulatory capacity of the
generated moDC populations. Using allogeneic MLR, no
obvious differences were observed between the different surfaces,
regardless of the DC population used as stimulator (Figure S4).
As expected, the co-culture with the immunogenic DC
populations (LPS and Jonuleit-cocktail stimulated cells) resulted
in higher proliferation compared to the immature control DC.
The proliferation of monocyte-depleted PBMC co-cultured with
the tolerogenic moDC populations was even less than with
immature DC. We further analyzed the immunogenic moDC
populations in an autologous setting. Both LPS- and Jonuleit-
cocktail stimulated cells were able to induce antigen specific
autologous CD4+ and CD8+ T cells, with slightly higher
numbers of IFN-γ producing T cells upon using LPS-stimulated
DC, independent of the culture dish used (Figure 4).
DISCUSSION
In this study, we analyzed the influence of the cell culture
surface on differentially stimulated moDC. The formation of cell
clusters was increased for all cells cultured on the non-adherent
culture dishes. Cell clusters on the standard culture dish were
in comparison very small and only forming after immunogenic
stimulation, suggesting a different clustering mechanism. The
phenotype was in many cases significantly modulated depending
on the cell culture dish. A total of 17 of the 25measured cytokines
were secreted at significantly different levels depending on the
culture dish by moDC stimulated with LPS. However, the T cell
stimulatory capacity was not influenced by the culture surface.
As immature DC are known to have tolerogenic functions
(12), and based on the similarities in phenotype and cytokine
production between the iDC and tolDC in our study, iDC/tolDC
will be discussed collectively. In contrast, due to the distinct
differences observed between LPS-DC and Jonuleit-DC, they will
be discussed separately.
Immature DC and Tolerogenic DC
The typical monocyte/macrophage marker CD14 was expressed
at high levels in all iDC/tolDC populations on the standard
culture dish, but at lower levels in the non-adherent culture dish,
with the exception of DexVD3 DC. This is in line with a previous
study showing that culturing monocytes in suspension rather
than adherent conditions leads to a rapid reduction in CD14
(13). Thus, using CD14 as a marker for successful DC generation
when comparing adherent with suspension protocols might not
be the best choice. Nevertheless, the prevention of the suggested
internalization of CD14 by DexVD3 treatment is interesting and
should be investigated further.
The lack of DC maturation marker CD83 on all iDC/tolDC
populations confirmed their immature state. Interestingly,
iDC cultured on non-adherent surfaces showed a slight but
statistically significant increase in CD1a, CD83, and CD80
expression, indicating that the formation of clusters might lead
to a “spontaneous” DC maturation. This hypothesis is further
strengthened by our observation that blocking CD11b, resulting
in increased homotypic clustering on the non-adherent surface,
also led to increased expression of costimulatory molecules
and MHC. This effect was not observed in the other tolDC
populations. However, further studies will have to investigate the
effect of the clustering on the tolerogenic function of the different
moDC populations in vitro and in vivo.
LPS Matured DC
LPS-stimulated moDC on standard cell culture dishes were, as
expected, CD83+ CD40high CD86high CD80+ MHC-IIhigh and
increasingly CCR7+. Using a non-adherent culture dish leading
FIGURE 4 | Antigen-specific T cell induction is not influenced by the culture dish conditions of the moDC. Autologous PBMC depleted of monocytes were co-cultured
with PPD-loaded DC generated on the indicated surface and matured with indicated stimuli for 7 days, and antigen-specific IFN-γ secretion by CD4+ and CD8+ cells
was analyzed by flow cytometry with LPS-DC as stimulators (± PPD). Delta LPS: moDC cultured on a conventional culture dish, stimulated with LPS; Hydrocell LPS:
moDC cultured on a non-adherent culture dish, stimulated with LPS; Delta Jonuleit: moDC cultured on a conventional culture dish, stimulated with Jonuleit cytokine
cocktail (TNF, IL-6, IL-1β, and PGE2 ); Hydrocell Jonuleit: moDC cultured on a non-adherent culture dish, stimulated with Jonuleit cytokine cocktail. Each color-coded
symbol represents results from one individual (n = 9).
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to the formation of clusters had a great impact on the phenotype
and cytokine secretion of the LPS-DC. Interestingly, based on
the CD83 expression, the percentage of mature DC did not
change, indicating that the observed changes reflect a change
of polarity but not maturation. Especially interesting was the
decrease in secretion of CC chemokine family members CCL3,
CCL4, and CCL5, which are all ligands of CCR1 and CCR5. These
chemokines attract mainly cells of the innate immune system like
granulocytes (14), monocytes/macrophages (15), NK cells (16),
mast cells (17), or immature dendritic cells (18) but also CD8+ T
cells (16, 19). Interestingly, IL-8, another chemokine of the innate
immune system attracting neutrophils (20), was not modulated
and secreted in equally high amounts. Strikingly, the chemokines
CXCL9 and CXCL10, both ERL-negative ligands of CXCR3, were
significantly more secreted. Especially CXCL10 had been nearly
absent on LPS-DC on the standard culture dish, but was secreted
by moDC on the non-adherent culture dish. Both chemokines of
the CXC family have been associated with supporting T helper 1
differentiation in vivo (21) but their receptor CXCR3 appears also
to be essential during wound healing (22). CXCL9 and CXCL10
have also been reported to recruit activated IFN-γ expressing NK
cells, CD8+ T cells and CD4+ T cells (23). The anti-inflammatory
cytokines IL-1RA, IL-2R, and IL10 were also secreted at lower
levels. Also IL-6 secretion was reduced considerably. IL-6 has
been associated with maintaining immature DC (24) but is also
linked to T helper 17 polarity (25). While IL-17 was not secreted
as much, it also was reduced upon use of non-adherent culture
dishes. Interestingly, IL-15 secretion was significantly increased
by LPS-DC cultured on a non-adherent cell culture dish. IL-15
is a cytokine secreted mainly by monocytes/macrophages and
dendritic cells (26, 27) and has gained a special interest as it
is required for the differentiation of NK cells, effector CD8+ T
cells and memory CD8+ T cells (26). IL-15 is also involved in
antiviral immunity by formation of IL-15-IL-15Rα complexes
able to induce IFN-γ mediated responses independent of type I
IFN (23).
Taken together, LPS-DC shift from a CC chemokine response
to a CXC chemokine response when modifying the culture dish
from a standard cell culturing condition to a non-adherent cell
culture dish. The high CD40 expression and high secretion of
chemoattractants by cells cultured on the standard cell culture
dish might be an example of an “all out” immune response,
which is only kept under control by anti- inflammatory cytokines
like IL-1RA, IL2R, and IL-10. The moderation of many of these
factors on the non-adherent culture dish combined with an
upregulation of CD86, IL-15, and the T cell chemoattractants
CXCL9 and CXCL10 suggest a rather directed response, probably
of a T helper 1 direction. Further in vitro and in vivo studies
are needed to analyze the functional impact of the non-adherent
culture dish during LPS- DC generation.
DC Matured With Jonuleit Cytokine
Cocktail
Interestingly, Jonuleit cytokine cocktail stimulated DC behaved
very differently than LPS-DC. CD83 expression was significantly
reduced when using a non-adherent cell culture dish, indicating
less mature DC. Thus, most of the other observed changes in
phenotype markers can be explained with the lower amount of
mature DC. Surprisingly, there was no significant difference in
the cytokine production except for GM-CSF between Jonuleit-
DC cultured on standard cell culture and non-adherent cell
culture dishes. In comparison to iDC/tolDC,most cytokines were
not secreted significantly different.
Taken together, the impact of the change in cell culture surface
seems more predictable for the Jonuleit DC. The use of a non-
adherent culture dish will probably not induce a different polarity
but would reduce the number of immunostimulatory DC. While
this is interesting with regard to in vivo mechanisms controlling
inflammation, a non-adherent cell culture surface might not be
the best choice when aiming at high numbers of immunogenic
DC to be used for immunotherapy, even though the T cell
induction capacity was not impaired. However, we here used a
recall antigen (PPD), and did not analyze the capacity to induce
naive T cells, meaning the effect of culture dish adherence on
DCs ability to process and present novel antigens remains to
be explored. This suggests that future studies on the matter
should consider utilizing another antigen with no prior memory
presence and isolate naïve T-cells with negative selection prior to
T cell induction capacity analysis. Another possibility to address
this question would be to test the T cell induction capacity of
DC on naïve T-cells from transgenic mice with known antigen
specificity. In our experiments, the cytokines contained in the
Jonuleit cocktail have rather broad inflammatory functions and
give more of a “danger” stimulus, while LPS binds to TLR4, an
innate pattern recognition receptor with specific function and
predefined certainty of pathogenic recognition. The close contact
with “self ” in the clusters might rather calm down the unspecific
stimulation. The LPS-DC on the other hand can rather be sure of
an immediate danger and can than only be modulated to change
polarity instead of remaining dormant. This gives an indication
of when the change to the non-adherent culture conditions might
lead to new subtypes of DC.
Possible Mechanisms for the Induction of
the Observed Culture Dish Dependent
Differences
Based on microscopy observations, the main consequence of
using a standard cell culture dish during moDC generation is an
early adherence phase, while moDC cultured on a non-adherent
surface form homotypic clusters. Usually, adherent monocytes
will detach during the first day in DC culture conditions
(10, 28). After the detachment, the characteristics of the cell
culture dish should not influence the floating cells any longer.
However, the early adhesion prevents the floating cells to cluster
afterwards. It is unclear if the early adhesion is only important to
control clustering or if the early adhesion alone already triggers
signaling pathways which will lead to the phenotype differences,
independent of the following clustering. Intriguingly, all three
integrins analyzed, CD11b, CD11c, and CD18, were significantly
higher expressed onmoDC cultured on the non-adherent culture
dishes (Figure 2). However, it is unclear if this is connected to the
mechanism inducing the phenotype changes. Integrin-binding
has been shown to induce DC maturation (29), and there is
evidence suggesting that the conversion of monocytes to DC can
be supported by specific integrin-binding (30).
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Based on the high expression levels, we chose to utilize
blocking antibodies against CD11a, CD11b, CD11c, CD18, and
E-cadherin. It has been shown previously that CD11d/CD18 and
CD11c/CD18 play a role in myeloid cell adhesion and spreading
(31, 32). Surprisingly, only anti-CD18 consistently reduced the
homotypic cluster formation in our study, suggesting other
additional molecules to be involved. In contrast, blocking CD11b
led to increased clustering in all our samples. This phenomenon
has previously been observed by another study on blocking
CD11b on moDC that suggests CD11b to be a competitive
inhibitor of other more prominent integrins, thus resulting in
stronger adhesive properties of moDC when blocked (33).
Homotypic clusters did not only form more intensively on
the non-adherent surface, but they also persisted over days, thus
showing a totally different dynamic as the early surface adhesion
on the standard adherent dish. However, as detached monocytes
on the standard dish did not form homotypic clusters prior to
stimulation, there might also be a different integrin regulation
involved in the homotypic aggregation at that point. Homotypic
clustering or aggregation of DC has been observed in vitro and
in vivo, but its natural function is unknown. However, support
for both maturation and antigen-transfer as possible mechanism
has been observed (34). It is tempting to speculate that differently
matured cell types like infiltrating monocytes, locally developing
DC and resident mature DC populations might cooperate in
this way, helping immature cells to mature and transfer the
original antigen-information to developing migrating cells in
order to stimulate the adaptive immune system without having
to abandon the site of inflammation. However, the effects
reported and assigned to the homotypic cluster formation
might also overlap with the reduction of integrin activation or
other interactions of the cells with their surroundings. Further
investigations will have to distinguish between these sources of
influence. Future experiments should also address other culture
surface conditions such as glass or other container conditions
such as culture bags.
CONCLUSIONS
The use of a non-adherent surface instead of a standard
culture dish can have a great impact on the phenotype and the
cytokine production of differently stimulated moDC. Further
investigations will be required in order to elucidate the molecular
mechanisms for the effect, but differences in the early direct
surface interactions and in the frequency and amount of cell-
cell interactions, influenced by homotypic cluster formation,
might play a deciding role. This study proves that monocytes
are crucially influenced by the near surrounding during the
development into dendritic cells. This has a potential application
for DC mediated immunotherapy, where the cellular phenotype
is essential for the success of the treatment.
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Supplementary file 
Figure S1: Homotypic cell clusters form on the non-adherent surface but less on the 
standard culture dish. Representative microscopy pictures of all generated DC populations 
at the end of the 3-day culture on a non-adherent culture dish (Nunc hydrocell) and a standard 
cell culture dish (Nunc delta). (n = 8) 
2 
Figure S2: The effect of blocking cell adhesion molecules on homotypic cell clustering. 
Representative images of moDC cultured in non- adherent surface dish (upper row) and on 
standard surface dish (lower row) with the addition of IgG1 (untreated), anti-CD11a, anti-
CD11b, anti-CD11c, anti-CD18, anti-E-Cadherin (anti-E-cad.) and a combination of all 
antibodies (Mix) after 3 days. Clustering on the non-adherent surface was notably reduced 
with the addition of anti-CD18 and increased with the addition of anti-CD11b. (n=5) 
3 
Figure S3: Improvement of the monocyte purity was achieved by further platelet 
removal. Representative Casy cell counter image overlay showing the initial monocyte purity 
with no further platelet removal (red) and with platelet removal using anti-CD61 microbeads 
(green). (n = 4)  
4 
Figure S4: Mixed leukocyte reaction (MLR). Three-day moDC cultured on standard culture 
dish (Nunc Delta) or non-adherent culture dish (Nunc Sphera) with the addition of indicated 
compounds were subsequently co-cultured with allogeneic CFDA-SE stained monocyte 
depleted PBMC for 5-7 days. DMSO: immature moDC with DMSO control; Jonuleit: moDC 
stimulated with (TNF, IL-6, IL-1 and PGE2); LPS: moDC stimulated with LPS; DexVD3: 
moDC cultured with dexamethasone and VD3; IL-10: moDC cultured with IL-10. Percentage 
cell proliferation of monocyte depleted PBMC was analyzed by flow cytometry and shown as 
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